-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AaR2vDK5BK7xjuGZrD1AfloE8xawTwCE/BVfrmX3gbv79Ah1T8ILFsj36v92KklH
 exEACTMiJx35OsOowqkfOw==

<SEC-DOCUMENT>0000950144-08-004306.txt : 20080521
<SEC-HEADER>0000950144-08-004306.hdr.sgml : 20080521
<ACCEPTANCE-DATETIME>20080521172653
ACCESSION NUMBER:		0000950144-08-004306
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20080521
DATE AS OF CHANGE:		20080521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-142535
		FILM NUMBER:		08852578

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>g06286b1sv1za.htm
<DESCRIPTION>CUMBERLAND PHARMACEUTICALS, INC. - FORM S-1/A
<TEXT>
<HTML>
<HEAD>
<TITLE>CUMBERLAND PHARMACEUTICALS, INC. - FORM S-1/A</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 91%; margin-left: 4%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> As filed with the Securities and Exchange Commission on
    May&#160;21, 2008</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Registration No. 333-142535</B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">Amendment No. 10</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt"> to</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt"><FONT style="white-space: nowrap">FORM&#160;S-1</FONT></FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">REGISTRATION
    STATEMENT</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">UNDER</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">THE SECURITIES ACT OF
    1933</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 24pt">Cumberland Pharmaceuticals
    Inc.</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B>Tennessee</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>2834</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>62-1765329</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification No.) </FONT></I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">2525&#160;West End Avenue,
    Suite&#160;950</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">Nashville, Tennessee
    37203</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">(615)&#160;255-0068</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number, including</FONT></I>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">area code, of registrant&#146;s
    principal executive offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">A.J. Kazimi</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">Chairman and CEO</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">2525&#160;West End Avenue,
    Suite&#160;950</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">Nashville, Tennessee
    37203</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 9pt">(615)&#160;255-0068</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number, including area code, of agent for
    service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>&#160;&#160;Martin S. Brown,&#160;Esq.<BR>
    Virginia Boulet,&#160;Esq.<BR>
    Adams and Reese LLP<BR>
    424 Church Street, Suite&#160;2800<BR>
    Nashville, Tennessee 37219<BR>
    <FONT style="white-space: nowrap">(615)&#160;259-1450</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Donald J. Murray,&#160;Esq.<BR>
    Dewey &#038; LeBoeuf LLP<BR>
    1301 Avenue of the Americas<BR>
    New York, New York 10019-6092<BR>
    (212) 259-8000</B>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed offering to the
    public:</B>&#160;&#160;As soon as practicable after this
    registration statement becomes effective.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this Form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act of 1933 check the
    following
    box:&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    please check the following box and list the Securities Act
    registration statement number of the earlier effective
    registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 16%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The registrant hereby amends this registration statement on
    such date or dates as may be necessary to delay its effective
    date until the registrant shall file a further amendment which
    specifically states that this registration statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933 or until the registration
    statement shall become effective on such date as the Commission,
    acting pursuant to said Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=504 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Information not
    required in prospectus
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">OTHER EXPENSES OF
    ISSUANCE AND DISTRIBUTION.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The expenses relating to the registration of the shares of
    common stock being offered hereby, other than underwriting
    discounts and commissions, will be borne by us. Such expenses
    are estimated to be as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Item</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Amount</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="4" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    FINRA filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASDAQ Global Market listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    271,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    875,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Blue sky, qualification fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transfer agent and registrar expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    803,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B>Total</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,300,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">INDEMNIFICATION
    OF DIRECTORS AND OFFICERS.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our charter and bylaws provide for indemnification of our
    directors to the fullest extent permitted by the Tennessee
    Business Corporation Act, as amended from time to time. Our
    directors shall not be liable to the corporation or its
    shareholders for monetary damages for breach of fiduciary duty
    as a director. The Tennessee Business Corporation Act provides
    that a Tennessee corporation may indemnify its directors and
    officers against expenses, judgments, fines and amounts paid in
    settlement actually and reasonably incurred by them in
    connection with any proceeding, whether criminal or civil,
    administrative or investigative if, in connection with the
    matter in issue, the individual&#146;s conduct was in good
    faith, and the individual reasonably believed: in the case of
    conduct in the individual&#146;s official capacity with the
    corporation, that the individual&#146;s conduct was in its best
    interest; and in all other cases, that the individual&#146;s
    behavior was at least not opposed to its best interest; and in
    the case of a criminal proceeding, the individual had no reason
    to believe the individual&#146;s conduct was unlawful. In
    addition, we have entered into indemnification agreements with
    our directors. These provisions and agreements may have the
    practical effect in certain cases of eliminating the ability of
    our shareholders to collect monetary damages from directors. We
    believe that these contractual agreements and the provisions in
    our charter and bylaws are necessary to attract and retain
    qualified persons as directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">RECENT SALES OF
    UNREGISTERED SECURITIES.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2003, we borrowed $500,000 from nine existing and
    accredited shareholders pursuant to uncollateralized secured
    notes payable with original maturity dates of 130&#160;days.
    These notes bore interest at 12% for the first 30&#160;days and
    15% thereafter. The holders of the notes had, at their option,
    until the maturity date of the notes payable, the right to
    convert all or a portion of the unpaid principal and interest
    into shares of our common stock at a rate of $6.00 per share. We
    also issued to these lenders options to purchase shares of our
    common stock, at an exercise price of $6.00&#160;per share, and
    at the rate of 3,080&#160;shares of common stock per $50,000
    face value of the notes. If we had not prepaid all amounts due
    and owing under the notes, we agreed to grant additional options
    at the rate of 1,540&#160;shares of common stock per $50,000
    face value on each of (i)&#160;the 30th&#160;day after the date
    of the notes and (ii)&#160;on a continuing basis, each
    successive
    <FONT style="white-space: nowrap">30-day</FONT>
    period thereafter, or portion thereof, as the notes remained
    outstanding. At December&#160;31, 2003, the notes payable had
    not been prepaid, so we
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-1</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    granted options to acquire an additional 61,600&#160;shares. We
    amended the notes agreements in January&#160;2004 to extend the
    maturity date 130&#160;days. The amendments granted an
    additional option to purchase 3,080&#160;shares per $50,000 face
    value upon extension of the notes and contained similar
    provisions for granting options in the event of nonpayment on
    the
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    due dates. Based on the extension of the maturity date, rights
    to purchase a total of 123,200&#160;shares were earned by the
    holders of the notes in 2004. We repaid these notes or settled
    these notes in shares in May 2004. The issuance of these
    securities was exempt from registration under the Securities Act
    in reliance on Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2003, we borrowed $1,000,000 from S.C.O.U.T.
    Healthcare Fund, L.P., or S.C.O.U.T., in the form of a
    convertible promissory note with a maturity date of September
    2004. The President and majority shareholder of the general
    partner of S.C.O.U.T., Dr.&#160;Lawrence W. Greer, serves on our
    board of directors. Pursuant to the terms of the note, on its
    maturity date, S.C.O.U.T. converted the principal value of the
    note plus all interest accrued at a fixed rate of ten percent
    per annum into 183,334&#160;shares of our common stock at a
    price of $6.00&#160;per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;15, 2004, we issued 86,000 common shares at
    $6.00&#160;per share, for an aggregate consideration of $516,000
    and a five-year warrant to purchase 40,000 common shares at
    $6.00&#160;per share to S.C.O.U.T., which represented to us that
    it was an accredited investor. This issuance was exempt from
    registration under the Securities Act in reliance on
    Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By an offering memorandum dated April&#160;1, 2005, we offered
    200,000&#160;shares of our common stock at a purchase price of
    $9.00&#160;per share. Thirty investors subscribed for
    200,000&#160;shares in the aggregate, for an aggregate
    consideration of $1,800,000. This issuance was exempt from
    registration under the Securities Act in reliance on
    Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By an offering memorandum dated May&#160;5, 2005, we received
    approximately $2,000,000 from approximately 41 investors in
    exchange for uncollateralized convertible promissory notes with
    a maturity date six months from the date of issuance. Upon
    maturity, the principal and accrued interest payable on the
    notes converted into 225,832&#160;shares of common stock at a
    rate of $9.00&#160;per share. This issuance was exempt from
    registration under the Securities Act in reliance on
    Section&#160;4(2) of the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2006, we issued a ten-year warrant to purchase 3,958
    common shares at $9.00 per share to Bank of America. The
    issuance of this security was exempt from registration under the
    Securities Act in reliance on Section&#160;4(2) of the
    Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since January&#160;1, 2004, we have granted options to purchase
    575,220&#160;shares of our common stock under the
    1999&#160;Option Plan to our employees, directors and
    consultants at exercise prices ranging from $6.00 to
    $11.00&#160;per share. Of these, an aggregate of
    1,650&#160;shares of our common stock were issued upon the
    exercise of stock options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since January&#160;1, 2004, we also issued an aggregate of
    151,290&#160;shares of common stock as compensation for services
    pursuant to contracts. Restricted-stock legends were affixed to
    the securities issued in these transactions. Our board of
    directors determined that the fair value of the services
    received equaled the value of the stock granted with values
    ranging from $6.00 to $11.00&#160;per share. The issuances of
    common stock in connection with awards of restricted stock were
    exempt either pursuant to Rule&#160;701 or pursuant to
    Section&#160;4(2) of the Securities Act as transactions by an
    issuer not involving a public offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The issuances of securities described in the first six
    paragraphs of Item&#160;15 were exempt from registration under
    the Securities Act of 1933, as amended, in reliance on
    Section&#160;4(2) of the Securities Act of 1933, as amended,
    and/or Regulation&#160;D promulgated thereunder, as transactions
    by an issuer not
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-2</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    involving any public offering. The purchasers of the securities
    in these transactions represented that they were accredited
    investors and they were acquiring the securities for investment
    only and not with a view toward the public sale or distribution
    thereof. Such purchasers received written disclosures that the
    securities had not been registered under the Securities Act of
    1933, as amended, and that any resale must be made pursuant to a
    registration statement or an available exemption from
    registration. All purchasers either received adequate financial
    statement or non-financial statement information about the
    registrant or had adequate access, through their relationship
    with the registrant, to financial statement or non-financial
    statement information about the registrant. The sale of these
    securities was made without general solicitation or advertising.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The issuances of securities described in the seventh and eighth
    paragraphs of Item&#160;15 were exempt from registration under
    the Securities Act of 1933, as amended, in reliance on either
    (1)&#160;Rule&#160;701 of the Securities Act of 1933, as
    amended, as offers and sales of securities pursuant to
    compensatory benefit plans and contracts relating to
    compensation in compliance with Rule&#160;701 or
    (2)&#160;Section&#160;4(2) of the Securities Act as transactions
    by an issuer not involving any public offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All certificates representing the securities issued in these
    transactions described in this Item&#160;15 included appropriate
    legends setting forth that the securities had not been offered
    or sold pursuant to a registration statement and describing the
    applicable restrictions on transfer of the securities. There
    were no underwriters employed in connection with any of the
    transactions set forth in this Item&#160;15.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">EXHIBITS AND
    FINANCIAL STATEMENT SCHEDULES.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="87%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Charter of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Bylaws of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of Cumberland Pharmaceuticals
    Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Warrant to Purchase Common Stock of Cumberland Pharmaceuticals
    Inc., issued to Bank of America, N.A. on October&#160;21, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.3**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Purchase Warrant, issued to S.C.O.U.T. Healthcare Fund
    L.P. on April&#160;15, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.4**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Warrant to Purchase Common Stock of Cumberland Pharmaceuticals
    Inc., issued to Bank of America, N.A. on April&#160;6, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.5#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Option Agreement under 1999 Stock Option Plan of
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6.1#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Incentive Stock Option Agreement under 2007 Long-Term
    Incentive Compensation Plan of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6.2#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Nonstatutory Stock Option Agreement under 2007 Long-Term
    Incentive Compensation Plan of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.7#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Nonstatutory Stock Option Agreement under
    2007&#160;Directors&#146; Compensation Plan of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    5.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Adams and Reese LLP.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.1&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Manufacturing and Supply Agreement for N-Acetylcysteine, dated
    January&#160;15, 2002, by and between Bioniche Life Sciences,
    Inc. and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Novation Agreement, dated January&#160;27, 2006, by and among
    Bioniche Life Sciences, Inc., Bioniche Pharma Group Ltd., and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
</TABLE>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-3</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>         <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="87%">&nbsp;</TD>         <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Manufacturing and Supply Agreement for
    N-Acetylcysteine, dated November&#160;16, 2006, by and between
    Bioniche Teoranta and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amendment to Manufacturing and Supply Agreement for
    N-Acetylcysteine, dated March&#160;25, 2008, by and between
    Bioniche Teoranta and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.4&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Cardinal Health Contract Sales and Services for Cumberland
    Pharmaceuticals Inc. Dedicated Sales Force Agreement, dated
    May&#160;16, 2006, by and between Cardinal Health  PTS, LLC and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.5&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Contract Sales and Service Agreement, dated
    July&#160;19, 2006, by and between Cardinal Health PTS, LLC and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amendment to Contract Sales and Service Agreement, dated
    June&#160;1, 2007, by and between Cumberland Pharmaceuticals
    Inc. and Inventiv Commercial Services, LLC, as successor in
    interest to Cardinal Health PTS, LLC.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Third Amendment to Contract Sales and Service Agreement, dated
    March&#160;26, 2008, by and between Cumberland Pharmaceuticals
    Inc. and Ventiv Commercial Services, LLC.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.7&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Services Agreement, dated August&#160;3, 2000, by
    and between CORD Logistics, Inc. and Cumberland Pharmaceuticals
    Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.8&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Strategic Alliance Agreement, dated July&#160;21, 2000, by and
    between F.H. Faulding&#160;&#038; Co. Limited and Cumberland
    Pharmaceuticals Inc., including notification of assignment from
    F.H. Faulding &#038; Co. Limited to Mayne Pharma Pty Ltd., dated
    April&#160;16, 2002
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Kristalose Agreement, dated April&#160;7, 2006, by and among
    Inalco Biochemicals, Inc., Inalco S.p.A., and Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Kristalose Agreement, dated April&#160;3, 2008, by
    and between Inalco S.p.A., Inalco Biochemicals, Inc., and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.10&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement, dated May&#160;28, 1999, by and between
    Vanderbilt University and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.11#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between A.J. Kazimi and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.12#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between Jean W. Marstiller and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.13#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between Leo Pavliv and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.14#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between J. William Hix and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.15#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between David L. Lowrance and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.1&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Loan Agreement by and between
    Cumberland Pharmaceuticals Inc. and Bank of America, N.A., dated
    April&#160;6, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Second Amended and Restated Loan Agreement by
    and between Cumberland Pharmaceuticals Inc. and Bank of America,
    N.A., dated December&#160;31, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.3**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amendment to Second Amended and Restated Loan Agreement
    by and between Cumberland Pharmaceuticals Inc. and Bank of
    America, N.A., dated July&#160;18,
    2007.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-4</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="87%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.4
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Third Amendment to Second Amended and Restated Loan Agreement,
    by and between Cumberland Pharmaceuticals Inc. and Bank of
    America, N.A., dated April&#160;6, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.17#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Option Plan of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.18#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2007 Long-Term Incentive Compensation Plan of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.19#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2007&#160;Directors&#146; Compensation Plan of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.20**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between Cumberland
    Pharmaceuticals Inc. and all members of its Board of Directors.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.21&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Lease Agreement, dated September&#160;10, 2005, by and between
    Nashville Hines Development, LLC and Cumberland Pharmaceuticals
    Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.21.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Office Lease Agreement, dated April&#160;25,
    2008, by and between 2525 West End, LLC (successor in interest
    to Nashville Hines Development LLC) and Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.22.1&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Sublease Agreement, dated December&#160;14, 2006, by and between
    Robert W. Baird&#160;&#038; Co. Incorporated and Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.22.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Addendum to Sublease Agreement, dated May&#160;5, 2007, by and
    between Robert W. Baird&#160;&#038; Co. Incorporated and
    Cumberland Pharmaceuticals Inc. and consented to by Nashville
    Hines Development, LLC.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.23&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Lease Agreement, dated November&#160;11,
    2004, by and between The Gateway to Nashville LLC and Cumberland
    Emerging Technologies, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.24**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Amended and Restated Lease Agreement, dated
    August&#160;23, 2005, by and between The Gateway to Nashville
    LLC and Cumberland Emerging Technologies, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.24.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Agreement to Amended and Restated Lease Agreement, dated
    January 9, 2006, by and between The Gateway to Nashville LLC and
    Cumberland Emerging Technologies, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.25&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Manufacturing Agreement, dated February 6, 2008, by and between
    Bayer HealthCare, LLC, and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    21**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subsidiaries of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of KPMG LLP.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Adams and Reese, LLP (contained in Exhibit&#160;5).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.3**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Morgan Joseph &#038; Co. Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    24**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Powers of Attorney (contained on the signature page of
    Registration Statement on Form&#160;S-1 filed on May&#160;1,
    2007).
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

    <DIV style="font-size: 12pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=128 iwidth=455 length=60 -->
</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#160;**&#160;</TD>
    <TD align="left">
    Previously filed.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="1%"></TD>
    <TD width="2%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#160;#&#160;
</TD>
    <TD align="left">
    Indicates a management contract or compensatory plan.
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#160;&#134;&#160;
</TD>
    <TD align="left">
    Confidential treatment has been granted for portions of this
    exhibit. These portions have been omitted from the Registration
    Statement and submitted separately to the Securities and
    Exchange Commission.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="1%"></TD>
    <TD width="2%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#134;&#134;&#160;
</TD>
    <TD align="left">
    Confidential treatment has been requested for portions of this
    exhibit. These portions have been omitted from the Registration
    Statement and submitted separately to the Securities and
    Exchange Commission.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    (b)&#160;&#160;</TD>
    <TD align="left">
    See Schedule&#160;II&#151;Valuation and qualifying accounts
    included in our audited financial statements included elsewhere
    in this registration statement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All other schedules have been omitted because they are not
    applicable.
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-5</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-family: Arial, Helvetica">Part II</FONT></B>
</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">ITEM&#160;17.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: Arial, Helvetica">UNDERTAKINGS.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriters at the closing specified in the underwriting
    agreement certificates in such denominations and registered in
    such names as required by the underwriters to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act of 1933 may be permitted to directors, officers,
    and controlling persons of the registrant pursuant to the
    foregoing provisions, or otherwise, the registrant has been
    advised that in the opinion of the Securities and Exchange
    Commission such indemnification is against public policy as
    expressed in the Securities Act of 1933 and is, therefore,
    unenforceable. In the event that a claim for indemnification
    against such liabilities (other than the payment by the
    registrant of expenses incurred or paid by a director, officer,
    or controlling person of the registrant in the successful
    defense of any action, suit, or proceeding) is asserted by such
    director, officer, or controlling person in connection with the
    securities being registered, the registrant will, unless in the
    opinion of its counsel the matter has been settled by
    controlling precedent, submit to a court of appropriate
    jurisdiction the question whether such indemnification by it is
    against public policy as expressed in the Securities Act of 1933
    and will be governed by the final adjudication of such issue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 7%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1)&#160;&#160;For purposes of determining any liability under
    the Securities Act of 1933, the information omitted from the
    form of prospectus filed as part of this Registration Statement
    in reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the Registrant pursuant to
    Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities
    Act shall be deemed to be part of this Registration Statement as
    of the time it was declared effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 7%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2)&#160;&#160;For the purpose of determining any liability under
    the Securities Act of 1933, each post-effective amendment that
    contains a form of prospectus shall be deemed to be a new
    Registration Statement relating to the securities offered
    therein, and the offering of such securities at that time shall
    be deemed to be the initial <I>bona fide </I>offering thereof.
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">II-6</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Signatures
    </FONT>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, the
    registrant has duly caused this Amendment No.&#160;10 to the
    Registration Statement to be signed on its behalf by the
    undersigned, thereunto duly authorized in the City of Nashville,
    State of Tennessee, on the
    21<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>&#160;day
    of May, 2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CUMBERLAND PHARMACEUTICALS INC.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="50%"></TD>
    <TD width="3%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="center">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">a.j.
    kazimi</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 3pt; margin-left: 53%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A.J. Kazimi<BR>
    Chairman and CEO<BR>
    (Principal Executive Officer)
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    Amendment No.&#160;10 to the Registration Statement has been
    signed by the following persons in the capacities and on the
    dates indicated.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="38%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="36%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Signature</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Title</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Date</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="7" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">a.j.
    kazimi</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->A.J.
    Kazimi
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Chairman and CEO (Principal Executive Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    May&#160;21, 2008
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">david
    l. lowrance</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->David
    L. Lowrance
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Vice President and CFO (Principal Financial and Accounting
    Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    May&#160;21, 2008
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">*</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Robert
    G. Edwards
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    May&#160;21, 2008
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">*</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Thomas
    R. Lawrence
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    May&#160;21, 2008
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">*</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Lawrence
    W. Greer
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    May&#160;21, 2008
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">*</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Martin
    E. Cearnal
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    May&#160;21, 2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
    *By:
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">a.j.
    kazimi</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;border-bottom: 1pt solid #000000"></DIV><!-- callerid=208 iwidth=174 length=0 -->A.J.
    Kazimi<BR>
    Attorney-in-Fact
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
  <DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt; font-family: Arial, Helvetica">S-1</FONT></B>
</DIV>
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="font-size: 4pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV style="margin-top: 14pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 16pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Exhibit&#160;Index
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="87%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description</FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Charter of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Bylaws of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of Cumberland Pharmaceuticals
    Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Warrant to Purchase Common Stock of Cumberland Pharmaceuticals
    Inc., issued to Bank of America, N.A. on October&#160;21, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.3**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Purchase Warrant, issued to S.C.O.U.T. Healthcare Fund
    L.P. on April&#160;15, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.4**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Warrant to Purchase Common Stock of Cumberland Pharmaceuticals
    Inc., issued to Bank of America, N.A. on April&#160;6, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.5#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Option Agreement under 1999 Stock Option Plan of
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6.1#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Incentive Stock Option Agreement under 2007 Long-Term
    Incentive Compensation Plan of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6.2#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Nonstatutory Stock Option Agreement under 2007 Long-Term
    Incentive Compensation Plan of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.7#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Nonstatutory Stock Option Agreement under
    2007&#160;Directors&#146; Compensation Plan of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    5.1**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Adams and Reese LLP.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.1&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Manufacturing and Supply Agreement for N-Acetylcysteine, dated
    January&#160;15, 2002, by and between Bioniche Life Sciences,
    Inc. and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Novation Agreement, dated January&#160;27, 2006, by and among
    Bioniche Life Sciences, Inc., Bioniche Pharma Group Ltd., and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Manufacturing and Supply Agreement for
    N-Acetylcysteine, dated November&#160;16, 2006, by and between
    Bioniche Teoranta and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amendment to Manufacturing and Supply Agreement for
    N-Acetylcysteine, dated March&#160;25, 2008, by and between
    Bioniche Teoranta and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.4&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Cardinal Health Contract Sales and Services for Cumberland
    Pharmaceuticals Inc. Dedicated Sales Force Agreement, dated
    May&#160;16, 2006, by and between Cardinal Health  PTS, LLC and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.5&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Contract Sales and Service Agreement, dated
    July&#160;19, 2006, by and between Cardinal Health PTS, LLC and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amendment to Contract Sales and Service Agreement, dated
    June&#160;1, 2007, by and between Cumberland Pharmaceuticals
    Inc. and Inventiv Commercial Services, LLC, as successor in
    interest to Cardinal Health PTS, LLC.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Third Amendment to Contract Sales and Service Agreement, dated
    March&#160;26, 2008, by and between Cumberland Pharmaceuticals
    Inc. and Ventiv Commercial Services, LLC.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.7&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Services Agreement, dated August&#160;3, 2000, by
    and between CORD Logistics, Inc. and Cumberland Pharmaceuticals
    Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.8&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Strategic Alliance Agreement, dated July&#160;21, 2000, by and
    between F.H. Faulding&#160;&#038; Co. Limited and Cumberland
    Pharmaceuticals Inc. including notification of assignment from
    F.H. Faulding &#038; Co. Limited to Mayne Pharma Pty Ltd., dated
    April&#160;16, 2002
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="87%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Kristalose Agreement, dated April&#160;7, 2006, by and among
    Inalco Biochemicals, Inc., Inalco S.p.A., and Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Kristalose Agreement, dated April&#160;3, 2008, by
    and between Inalco S.p.A., Inalco Biochemicals, Inc., and
    Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.10&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement, dated May&#160;28, 1999, by and between
    Vanderbilt University and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.11#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between A.J. Kazimi and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.12#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between Jean W. Marstiller and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.13#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between Leo Pavliv and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.14#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between J. William Hix and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.15#
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement effective as of January&#160;1, 2008 by and
    between David L. Lowrance and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.1&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Loan Agreement by and between
    Cumberland Pharmaceuticals Inc. and Bank of America, N.A., dated
    April&#160;6, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Second Amended and Restated Loan Agreement by
    and between Cumberland Pharmaceuticals Inc. and Bank of America,
    N.A., dated December&#160;31, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.3**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amendment to Second Amended and Restated Loan Agreement
    by and between Cumberland Pharmaceuticals Inc. and Bank of
    America, N.A., dated July&#160;18, 2007.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16.4
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Third Amendment to Second Amended and Restated Loan Agreement,
    by and between Cumberland Pharmaceuticals Inc. and Bank of
    America, N.A., dated April&#160;6, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.17#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Option Plan of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.18#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2007 Long-Term Incentive Compensation Plan of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.19#**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2007&#160;Directors&#146; Compensation Plan of Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.20**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between Cumberland
    Pharmaceuticals Inc. and all members of its Board of Directors.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.21&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Lease Agreement, dated September&#160;10, 2005, by and between
    Nashville Hines Development, LLC and Cumberland Pharmaceuticals
    Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.21.1&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Office Lease Agreement, dated April&#160;25,
    2008, by and between 2525 West End, LLC (successor in interest
    to Nashville Hines Development LLC) and Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.22.1&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Sublease Agreement, dated December&#160;14, 2006, by and between
    Robert W. Baird&#160;&#038; Co. Incorporated and Cumberland
    Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.22.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Addendum to Sublease Agreement, dated May&#160;5, 2007, by and
    between Robert W. Baird&#160;&#038; Co. Incorporated and
    Cumberland Pharmaceuticals Inc. and consented to by Nashville
    Hines Development, LLC.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.23&#134;**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Lease Agreement, dated November&#160;11,
    2004, by and between The Gateway to Nashville LLC and Cumberland
    Emerging Technologies, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.24**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Amended and Restated Lease Agreement, dated
    August&#160;23, 2005, by and between The Gateway to Nashville
    LLC and Cumberland Emerging Technologies, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.24.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Agreement to Amended and Restated Lease Agreement, dated
    January 9, 2006, by and between The Gateway to Nashville LLC and
    Cumberland Emerging Technologies, Inc.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="87%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">No.</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-family: Arial, Helvetica">Description
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="3" align="left" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.25&#134;&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Manufacturing Agreement, dated February 6, 2008, by and between
    Bayer HealthCare, LLC, and Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    21**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subsidiaries of Cumberland Pharmaceuticals Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of KPMG LLP.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.2**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Adams and Reese, LLP (contained in Exhibit&#160;5).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.3**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Morgan Joseph &#038; Co. Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    24**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Powers of Attorney (contained on the signature page of the
    Registration Statement on Form&#160;S-1 filed on May&#160;1,
    2007).
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

    <DIV style="font-size: 12pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=128 iwidth=455 length=60 -->
</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="16%"></TD>
    <TD width="84%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    **&#160;Previously filed.</TD>
    <TD align="left">

</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    #&#160;&#160;
</TD>
    <TD align="left">    Indicates a management contract or compensatory plan.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#134;&#160;&#160;
</TD>
    <TD align="left">    Confidential treatment has been granted for portions of this
    exhibit. These portions have been omitted from the Registration
    Statement and submitted separately to the Securities and
    Exchange Commission.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#134;&#134;&#160;</TD>
    <TD align="left">
    Confidential treatment has been requested for portions of this
    exhibit. These portions have been omitted from the Registration
    Statement and submitted separately to the Securities and
    Exchange Commission.
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3.1
<SEQUENCE>2
<FILENAME>g06286b1exv10w3w1.htm
<DESCRIPTION>EX-10.3.1 SECOND AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.3.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.3.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment<BR>
which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDMENT TO MANUFACTURING AND SUPPLY AGREEMENT<BR>
FOR N-ACETYLCYSTEINE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS SECOND AMENDMENT (the &#147;<U>Second Amendment</U>&#148;) to that certain Manufacturing and
Supply Agreement for N-Acetylcysteine, dated as of January&nbsp;15, 2002 (the &#147;<U>Original
Agreement</U>&#148;), as modified by that certain Novation Agreement, dated as of January&nbsp;27, 2006 (the
&#147;<U>Novation Agreement</U>&#148;), and as amended by that certain First Amendment to Manufacturing and
Supply Agreement for N-Acetylcyesteine dated as of November&nbsp;16, 2006 (the &#147;<U>First
Amendment</U>&#148;) is entered into by and between CUMBERLAND PHARMACEUTICALS INC., a corporation
organized and existing under the laws of Tennessee, United States (&#147;<U>CUMBERLAND</U>&#148;), and
BIONICHE TEORANTA, a corporation organized and existing under the laws of Ireland
(&#147;<U>BIONICHE</U>&#148;), and is effective as of March&nbsp;25, 2008 (The Original Agreement, the Novation
Agreement, and the First Amendment are collectively referred to herein as the &#147;<U>Agreement</U>&#148;).
Capitalized terms used but not defined in this Second Amendment shall have the meanings that are
set forth in the Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WITNESSETH:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, BIONICHE is the assignee under the Agreement of BIONICHE PHARMA GROUP LIMITED, an
Affiliate thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual covenants, agreements, representation and
warranties contained herein, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties hereto hereby agree as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;1.18 defines <B>TERRITORY </B>as having the meaning set
forth in Schedule&nbsp;III. Schedule&nbsp;III of the Agreement, and therefore the
TERRITORY, is hereby amended and restated as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The United States of America, Australia, New Zealand, Singapore, Malaysia,
Hong Kong, China, Vietnam, Thailand, Taiwan, Korea, the Philippines and each
of their territories and possessions on the Effective Date of this Second
Amendment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Paragraph&nbsp;5.6 is hereby amended by adding clause (d)&nbsp;as
follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(d)&nbsp;Notwithstanding the foregoing, CUMBERLAND may establish a
secondary supply arrangement with a third party. For Drug Product manufactured
by a third party supplier for commercial sale by CUMBERLAND during the term of
the Original Agreement, CUMBERLAND will pay BIONICHE at a rate of &#091;***&#093; CDN
for each 30 mL vial of the Drug Product that CUMBERLAND purchases from such
third party. Payment will be made by CUMBERLAND to BIONICHE within &#091;***&#093; days
after the Drug Product is delivered by the third party and released for sale by
CUMBERLAND.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following is hereby added to the end of Paragraph&nbsp;2.7 of the existing
Agreement:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that CUMBERLAND arranges to sell Drug Product or have Drug
Product sold in a region or market whose regulatory authority requires a
unique label; or if CUMBERLAND contracts a third party to sell Drug Product,
and this third party requires a unique label, then BIONICHE shall divide the
Labeling of Drug Product in the applicable Purchase Order between the unique
label and the usual and customary CUMBERLAND label in accordance with
CUMBERLAND&#146;s request. In such an event, CUMBERLAND will provide such unique
label to BIONICHE and clearly identify the division of Drug Product between
the two labels on any applicable Purchase Order.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon request by CUMBERLAND, BIONICHE will ship a whole or partial Order of the
Drug Product to fulfill the commitments in a given region or market directly
to a secondary distributor or to a third party or its identified distributor.
In such an event, CUMBERLAND will identify on the applicable Purchase Order
the requested shipment destination and any shipping instructions.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the section entitled &#147;Pricing&#148; in SCHEDULE I, the first
paragraph is hereby amended and restated as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Paragraph&nbsp;2.10(a) of the Original Agreement, the price to be paid
by CUMBERLAND to BIONICHE in the year 2008 for the Drug Products ordered from
BIONICHE is as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">N-acetylcysteine 30 mL &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canadian &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $&#091;***&#093;
</DIV>


<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Any price adjustment after 2008 shall be made in accordance with Paragraph
2.10(b)</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the section entitled &#147;Pricing&#148; in SCHEDULE I, the first
sentence of the fourth paragraph is hereby amended and restated as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In addition, CUMBERLAND shall pay to BIONICHE a royalty equal to &#091;***&#093; percent
(&#091;***&#093;%) of Net Sales (as defined herein) during each calendar year through
December&nbsp;31, 2010, and during the period thereafter ending January&nbsp;23, 2011 on
product manufactured by BIONICHE or by a 3<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP> party contractor for
CUMBERLAND provided that CUMBERLAND shall pay BIONICHE such royalty on a
quarterly basis within &#091;***&#093; days after the last day of the applicable
calendar quarter.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Miscellaneous.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(a) <U>Authorization</U>. Each party to this Second Amendment hereby
represents and warrants that the execution, delivery and performance of this
Second Amendment is within the powers of such party and has been duly
authorized by the party, is in accordance with all applicable laws and
regulations, and this Second Amendment constitutes the valid and enforceable
obligation of each party in accordance with its terms.</DIV>


<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(b) <U>Effect of Second Amendment</U>. Each party acknowledges that this
Second Amendment constitutes a written instrument as contemplated by Paragraph
11.2 of the Agreement. Except as specifically amended above, the Agreement
shall remain in full force and effect, and is hereby ratified and confirmed.</DIV>


<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(c) <U>Counterparts</U>. This Second Amendment may be executed in any number
of counterparts, each of which may be executed by only one of the parties
hereto, and each of which shall be enforceable against the party actually
executing such counterpart, and all of which shall together constitute one
instrument.</DIV>


<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(d) <U>Titles and Subtitles</U>. The titles and subtitles used in this
Second Amendment are used for convenience only and are not to be considered in
construing or interpreting this Second Amendment.</DIV>


<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(e) <U>Governing Law and Dispute Resolution</U>. This Second Amendment shall
be construed in accordance with the laws of the State of New York without
regard to applicable conflicts of laws provisions and any dispute,
controversy, or claim arising out of or relating to this Second Amendment
shall be governed by the provisions of Paragraph&nbsp;11.7 of the Agreement.</DIV>


<DIV align="left" style="margin-left: 6%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">(f) <U>Severability</U>. Should any part of this Second Amendment be invalid
or unenforceable, such invalidity or unenforceability shall not affect the
validity and enforceability of the remaining portion.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, each of the undersigned has caused this Second Amendment to be effective as of
the date first above written.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>CUMBERLAND:</B><BR>
<BR>
<BR>
CUMBERLAND PHARMACEUTICALS INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A. J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 49%">Date: <U>March&nbsp;25, 2008</U>

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BIONICHE:</B><BR>
<BR>
<BR>
BIONICHE TEORANTA<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ George Zorich
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">George S Zorich&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President, North American Operations&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 49%">Date: <u>April&nbsp;1, 2008</u>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6.1
<SEQUENCE>3
<FILENAME>g06286b1exv10w6w1.htm
<DESCRIPTION>EX-10.6.1 THIRD AMENDMENT TO CONTRACT SALES AND SERVICE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.6.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.6.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>THIRD AMENDMENT<BR>
TO<BR>
CONTRACT SALES AND SERVICE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Third Amendment to Contract Sales and Service Agreement (&#147;Third Amendment&#148;) is entered
into as of March&nbsp;26, 2008, by and between VENTIV COMMERCIAL SERVICES, LLC, a New Jersey limited
liability company d/b/a as Inventiv Commercial, LLC (&#147;Ventiv&#148;) and Cumberland Pharmaceuticals, Inc.
a Tennessee corporation (&#147;Cumberland&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">W I T N E S S E T H
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Ventiv, as successor in interest to Cardinal Health PTS, LLC, and Cumberland are
parties to that certain Contract Sales and Service Agreement dated as of May&nbsp;16, 2006, as amended,
by that First Amendment to Contract Sales and Service Agreement dated as of July&nbsp;19, 2006 and that
Second Amendment to Contract Sales and Service Agreement dated June&nbsp;1, 2007 (collectively, the
&#147;Service Agreement&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Ventiv and Cumberland desire to lengthen the period covered by the Service Agreement
and to make certain other adjustments to the terms and conditions of the Service Agreement as set
forth in this Third Amendment; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, capitalized terms used herein without definition shall have the respective meanings
ascribed thereto in the Service Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the premises and other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, it is agreed as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Section&nbsp;1 of the First Amendment to Contract Sales and Service Agreement dated July&nbsp;19,
2006, the description of the Syndicated Sales Force is hereby deleted in its entirety.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Section&nbsp;2.1 of the Service Agreement shall be amended to provide that Ventiv shall provide
Cumberland with an additional fourteen (14)&nbsp;Representatives (&#147;Additional Representatives&#148;) for a
total of thirty-eight (38)&nbsp;full-time Representatives commencing on or about March&nbsp;10, 2008 (the
&#147;Hire Date&#148;). The Additional Representatives shall provide the services of the Representatives set
forth in the Service Agreement. In connection with the Product Detail, Ventiv shall provide the
following services:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Implementation</U> &#151; recruit and train the Additional Representatives, with training
consisting of five (5)&nbsp;days of home study and five (5)&nbsp;days of initial training to commence on
March&nbsp;17, 2008 (the &#147;Training Date&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Deployment</U> &#151; (i)&nbsp;Deployment of the thirty-eight (38)&nbsp;Representatives (base salary,
benefits, handheld PDA&#146;s and laptops (including sales force automation software), printers and
bonus targeted at &#091;***&#093; of base salary), (ii)&nbsp;four (4)&nbsp;Managers (base salary, benefits, laptops
(including sales force automation software), printers, and bonus targeted at &#091;***&#093; of base salary),
and (iii)&nbsp;turnover training and recruiting and (iv)&nbsp;office costs/operational supplies. As set
forth in this Agreement, &#147;Deployment&#148; or &#147;Deployment Date&#148; means the date the Representatives
commence Product Detailing pursuant to the Service
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement. The Representatives will be deployed and commence Product Detailing on or about March
24, 2008 (the &#147;Deployment&#148; or &#147;Deployment Date&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Section&nbsp;2.2 of the Service Agreement shall be amended to provide that Ventiv shall provide
Cumberland with an additional two (2)&nbsp;Managers (&#147;Additional Managers&#148;) for a total of four (4)
Managers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Delete the first sentence of Section&nbsp;2.3(f) in its entirety.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;In Section&nbsp;2.6 of the Service Agreement, delete all references to &#147;six (6)&#148; and replace
with &#147;four (4)&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Section&nbsp;14 of the Service Agreement is amended to provide that the Agreement shall be
extended as of the Effective Date, until April&nbsp;1, 2010 (the &#147;Renewal Term&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Schedule&nbsp;3.1 of the Service Agreement shall be deleted in its entirety and replaced with
the attached Schedule&nbsp;3.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;The validity of this Third Amendment, its construction, interpretation and enforcement, the
rights of the parties hereunder, shall be determined under, governed by, and construed in
accordance with the laws of the State of Tennessee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;This Third Amendment may be executed in any number of counterparts, each of which, when
executed, shall be deemed to be an original and all of which together shall constitute one and the
same document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;Except as expressly amended by this Third Amendment, the Service Agreement remains in full
force and effect in accordance with its terms and hereby is ratified and conformed in all respects.
The execution, delivery, and performance of this Third Amendment shall not, except as expressly
set forth herein, operate as an amendment of any right, power or remedy under the Service
Agreement, as in effect prior to the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Upon and after the effectiveness of this Third Amendment, each reference in the Service
Agreement to &#147;this Agreement&#148;, &#147;hereunder&#148;, &#147;herein&#148;, &#147;hereof&#148; or words of like import referring to
the Service Agreement shall mean and be a reference to the Service Agreement as modified and
amended hereby. To the extent that any terms and conditions of the Service Agreement shall
contradict or be in conflict with any terms and conditions of this Third Amendment, such terms and
conditions are hereby deemed modified or amended accordingly to reflect the terms and conditions of
the Service Agreement as modified or amended hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;This Third Amendment embodies the entire understanding and agreement between the parties
hereto with respect to the subject matter hereof and supercedes all prior agreements,
understandings, and inducements, whether express or implied, oral or written.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Third Amendment to be executed by
their duly authorized representatives as of the date and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">VENTIV COMMERCIAL SERVICES, LLC<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Terrell G. Herring
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Terrell G. Herring&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President and CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CUMBERLAND PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SCHEDULE 3.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">COMPENSATION &#151; IMPLEMENTATION FEES, FIXED FEES AND PASS-THROUGH<BR>
COSTS AND BILLING TERMS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I. <U>FIXED FEES</U>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Implementation Fee</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland shall pay Ventiv an Implementation Fee for the Additional Representatives and the
Additional Managers in the amount of $&#091;***&#093; within &#091;***&#093; days after the Effective Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fixed Monthly Fee</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland shall pay Ventiv a Fixed Monthly Fee as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="90%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Monthly Fee Commencing<br>
on the Effective Date and <BR>
Continuing Until the Hire <BR>
Date</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Monthly Fee<BR>
Commencing on the Hire<BR>
Date and Continuing<BR>
Until the First<BR>
Anniversary of the Hire<BR>
Date</B></FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Monthly Fee<BR>
Commencing on the First<BR>
Anniversary of the Hire<BR>
Date and Continuing<BR>
Until the Second<BR>
Anniversary of the Hire<BR>
Date</B></FONT></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">$258,482
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$442,484
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">$453,615</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. PASS-THROUGH COSTS</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the Fixed Fees, certain expenses will be charged to Cumberland on
a pass-through basis. These expenses will be billed to Cumberland at actual cost incurred by
Ventiv. Pass through expenses shall include:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt"> &#151;  Manager Bonus (including employer portion of taxes)<BR>
 &#151;  Representative Bonus (including employer portion of taxes)<BR>
 &#151;  Manager travel (air, rail, rental, taxi, lodging and meals)<BR>
 &#151;  Representative travel (air, rail, rental, taxi, lodging and meals)<BR>
 &#151;  Postage associated with initial shipment of training materials<BR>
 &#151;  National Training Meeting<BR>
 &#151;  District Planning Meetings and National Sales Meetings<BR>
 &#151;  Third Party data acquisition costs
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt"> &#151;  Promotional Funds<BR>
 &#151;  Physician Validation<BR>
 &#151;  Sample Storage<BR>
 &#151;  Travel Associated with Interviews
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, airline travel shall be via commercial airline at no more than
full coach fare, and each Manager Bonus and Representative Bonus shall be in an amount agreed in
writing by Cumberland and Ventiv before payment thereof and shall be based upon
well-defined, mutually agreed performance criteria, subject to Ventiv&#146;s internal human resources
policies and procedures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>III. BILLING TERMS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cumberland will be billed monthly in arrears the amount stated above as the Fixed Monthly Fee.
Pass-through Costs will be billed to Cumberland at actual cost as incurred by Ventiv.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Invoices are due &#091;***&#093; days from date of invoice. If not paid within &#091;***&#093; days of the date
of invoice, there will be a finance charge of 1.5% monthly, applied to the outstanding balance due.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9.1
<SEQUENCE>4
<FILENAME>g06286b1exv10w9w1.htm
<DESCRIPTION>EX-10.9.1 AMENDMENT TO KIRISTALOSE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.9.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.9.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT TO<BR>
KRISTALOSE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment to Kristalose Agreement (the &#147;Amendment&#148;) is entered into this 3<SUP style="font-size: 85%; vertical-align: text-top">rd</SUP>
day of April, 2008 by and between Inalco S.P.A. (&#147;Inalco Italy&#148;), Inalco Biochemicals, Inc.
(&#147;Inalco U.S.&#148;) and Cumberland Pharmaceuticals Inc. (&#147;Cumberland&#148;). Inalco Italy and Inalco U.S.
are hereinafter collectively referred to as &#147;Inalco.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Inalco and Cumberland entered into a certain Kristalose Agreement in April&nbsp;2006 (the
&#147;Agreement&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>Inalco and Cumberland desire to amend the Kristalose Agreement in certain respects as
set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>for and in consideration of the mutual covenants and agreements hereinafter
set forth, and for other good and valuable consideration, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U><B>Amendment of Section&nbsp;4.1</B></U>. Subsection C. (Third Installment) of Section&nbsp;4.1 of the
Agreement is hereby amended by deleting &#147;Three Million U.S. Dollars ($3,000,000 U.S.), payable upon
the third anniversary of the Effective Date of this Agreement&#148; and substituting in lieu thereof
&#147;Two Million Seven Hundred Sixty Thousand U.S. Dollars ($2,760,000 U.S.), payable within seven (7)
days of the date of this Amendment.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U><B>Amendment of Section&nbsp;4.2</B></U>. Section&nbsp;4.2 (Royalty Payment) is hereby amended by
deleting from Subsection B. thereof &#147;&#091;***&#093;&#148; and substituting in lieu thereof &#147;&#091;***&#093;&#148;. Section&nbsp;4.2
is hereby further amended by deleting from Subsection C. thereof &#147;&#091;***&#093;&#148; and substituting in lieu
thereof &#147;&#091;***&#093;.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U><B>Amendment of Section&nbsp;4.3</B></U>. Effective the date of this Amendment, Section&nbsp;4.3
(Payment for Product) is hereby amended to reflect a one-time price increase by deleting &#147;&#091;***&#093;&#148;
and substituting in lieu thereof &#147;&#091;***&#093;&#148; and by deleting &#147;&#091;***&#093;&#148; and substituting in lieu thereof
&#147;&#091;***&#093;.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Capitalized terms not defined in this Amendment shall have the meaning set forth in the
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;It is mutually agreed that all covenants, conditions and agreements set forth in the
Agreement (as amended hereby) shall remain binding upon the parties and inure to the benefit of the
parties hereto and their respective successors and assigns.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF, </B>the parties hereto have caused this Amendment to be executed by their duly
authorized representatives effective as of the day and year first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>INALCO S.P.A</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Giovanni Cipolletti
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Giovanni Cipolletti&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its: President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>INALCO BIONCHEMICALS, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Eric Lowe
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Eric Lowe                  &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its: President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>CUMBERLAND PHARMACEUTICALS INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A.J. Kazimi                 &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its: Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16.4
<SEQUENCE>5
<FILENAME>g06286b1exv10w16w4.htm
<DESCRIPTION>EX-10.16.4 THIRD AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.16.4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.16.4</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>THIRD AMENDMENT TO<BR>
SECOND AMENDED AND RESTATED LOAN AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIS THIRD AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AGREEMENT </B>(this &#147;<U>Amendment</U>&#148;),
dated April&nbsp;6, 2008, is made and entered into on the terms and conditions hereinafter set forth, by
and between CUMBERLAND PHARMACEUTICALS, INC., a Tennessee corporation (the &#147;<U>Borrower</U>&#148;), and
BANK OF AMERICA, N.A., a national banking association (the &#147;<U>Bank</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The Borrower and the Bank are parties to a Second Amended and Restated Agreement dated as
of April&nbsp;6, 2006, as amended by that certain First Amendment to Second Amended and Restated Loan
Agreement dated as of December&nbsp;31, 2006, as further amended by that certain Second Amendment to
Second Amended and Restated Loan Agreement dated as of July&nbsp;18, 2007 (as the same heretofore has
been or hereafter may be further amended, restated, supplemented, extended, renewed, replaced or
otherwise modified from time to time, the &#147;<U>Loan Agreement</U>&#148;), pursuant to which the Bank has
agreed to extend credit to the Borrower subject to and upon the terms and conditions set forth in
the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The parties hereto desire to amend the Loan Agreement in certain respects as more
particularly hereinafter set forth.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Capitalized terms used but not otherwise defined in this Amendment shall have the same
meanings as in the Loan Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENTS:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW, THEREFORE, </B>in consideration of the mutual covenants and agreements hereinafter set forth,
and for other good and valuable consideration, the receipt and sufficiency of all of which are
hereby acknowledged, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;</B><U><B>Amendment of Section&nbsp;1.2</B></U><B>. </B>Section&nbsp;1.2 (Availability Period) of the Loan Agreement
is hereby amended by deleting the last sentence of Section&nbsp;1.2 and substituting the following in
lieu thereof:
</DIV>

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Thereafter, the maximum availability under the Facility No.&nbsp;1 Commitment shall be
$4,000,000 until the third (3rd) anniversary of the date of this Agreement, or such
earlier date as the availability may terminate as provided in this Agreement (the
&#147;<U>Facility No.&nbsp;1 Expiration Date</U>&#148;).</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;</B><U><B>Representations and Warranties of the Borrower</B></U><B>. </B>As an inducement to the Bank to
enter into this Amendment, the Borrower hereby represents and warrants that on and as of the date
hereof, and taking into account the provisions hereof, the representations and warranties contained
in the Loan Agreement and the other Loan Documents are true and correct in all material respects,
except for representations and warranties that expressly relate to an earlier date, which remain
true and correct as of said earlier date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;</B><U><B>Effect of Amendment; Continuing Effectiveness of Loan Agreement and Loan Documents</B></U><B>.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Neither this Amendment nor any other indulgences that may have been granted to the
Borrower by the Bank shall constitute a course of dealing or otherwise obligate the Bank to
modify, expand or extend the agreements contained herein, to agree to any other amendments
to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">the Loan Agreement or to grant any consent to, waiver of or indulgence with respect to any
other noncompliance with any provision of the Loan Documents.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Upon and after the effectiveness of this Amendment, each reference in the Loan
Agreement to &#147;this Agreement&#148;, &#147;hereunder&#148;, &#147;hereof&#148; or words of like import referring to
the Loan Agreement, and each reference in the other Loan Documents to &#147;the Loan Agreement&#148;,
&#147;thereunder&#148;, &#147;thereof&#148; or words of like import referring to the Loan Agreement, shall mean
and be a reference to the Loan Agreement as modified hereby. This Amendment shall
constitute a Loan Document for all purposes of the Loan Agreement and the other Loan
Documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>Except to the extent amended or modified hereby, the Loan Agreement, the other Loan
Documents and all terms, conditions and provisions thereof shall continue in full force and
effect in all respects and shall be construed in accordance with the modification of the
Loan Agreement effected hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;</B><U><B>Release and Waiver</B></U><B>. </B>The Borrower hereby stipulates, acknowledges and agrees that
it has no claims or causes of action of any kind whatsoever against the Bank arising out of or
relating in any way to any event, circumstance, action or failure to act with respect to this
Amendment, the Loan Agreement, the other Loan Documents or any matters described or referred to
herein or therein or otherwise related hereto or thereto. The Borrower hereby releases the Bank
from any and all claims, causes of action, demands and liabilities of any kind whatsoever, whether
direct or indirect, fixed or contingent, liquidated or unliquidated, disputed or undisputed, known
or unknown, that the Borrower may now or hereafter have and that arise out of or relate in any way
to any event, circumstance, action or failure to act on or before the date of this Amendment with
respect to this Amendment, the Loan Agreement, the other Loan Documents or any matters described or
referred to herein or therein or otherwise related hereto or thereto. The release by the Borrower
herein, together with the other terms and provisions of this Amendment, are entered into by the
Borrower advisedly and without compulsion, coercion or duress, the Borrower having determined that
this Amendment is in the economic best interests of the Borrower. The Borrower represents that it
is entering into this Amendment freely and with the advice of counsel as to its legal alternatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;</B><U><B>Further Actions</B></U><B>. </B>Each of the parties to this Amendment agrees that at any time and
from time to time upon written request of the other party, it will execute and deliver such further
documents and do such further acts and things as such other party reasonably may request in order
to effect the intents and purposes of this Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;</B><U><B>Counterparts</B></U><B>. </B>This Amendment may be executed in multiple counterparts or copies,
each of which shall be deemed an original hereof for all purposes. One or more counterparts or
copies of this Amendment may be executed by one or more of the parties hereto, and some different
counterparts or copies executed by one or more of the other parties. Each counterpart or copy
hereof executed by any party hereto shall be binding upon the party executing same even though
other parties may execute one or more different counterparts or copies, and all counterparts or
copies hereof so executed shall constitute but one and the same agreement. Each party hereto, by
execution of one or more counterparts or copies hereof, expressly authorizes and directs any other
party hereto to detach the signature pages and any corresponding acknowledgment, attestation,
witness or similar pages relating thereto from any such counterpart or copy hereof executed by the
authorizing party and affix same to one or more other identical counterparts or copies hereof so
that upon execution of multiple counterparts or copies hereof by all parties hereto, there shall be
one or more counterparts or copies hereof to which is(are) attached signature pages containing
signatures of all parties hereto and any corresponding acknowledgment, attestation, witness or
similar pages relating thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;</B><U><B>Miscellaneous</B></U><B>.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>This Amendment shall be governed by, construed and enforced in accordance with the
laws of the State of Tennessee, without reference to the conflicts or choice of law
principles thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>The headings in this Amendment and the usage herein of defined terms are for
convenience of reference only, and shall not be construed as amplifying, limiting or
otherwise affecting the substantive provisions hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>All references herein to the preamble, the recitals or sections, paragraphs,
subparagraphs, annexes or exhibits are to the preamble, recitals, sections, paragraphs,
subparagraphs, annexes and exhibits of or to this Amendment unless otherwise specified. The
words &#147;hereof&#148;, &#147;herein&#148; and &#147;hereunder&#148; and words of similar import, when used in this
Amendment, refer to this Amendment as a whole and not to any particular provision of this
Amendment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>Any reference herein to any instrument, document or agreement, by whatever
terminology used, shall be deemed to include any and all amendments, modifications,
supplements, extensions, renewals, substitutions and/or replacements thereof as the context
may require.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e) </B>When used herein, (1)&nbsp;the singular shall include the plural, and vice versa, and
the use of the masculine, feminine or neuter gender shall include all other genders, as
appropriate, (2) &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; shall be deemed to be followed by
&#147;without limitation&#148; regardless of whether such words or words of like import in fact follow
same, and (3)&nbsp;unless the context clearly indicates otherwise, the disjunctive &#147;or&#148; shall
include the conjunctive &#147;and&#148;.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;Remainder of Page Intentionally Left Blank;<BR>
Signature Pages Follow&#093;</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF, </B>the parties hereto have caused this Amendment to be duly executed and
delivered as of the date first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BORROWER:</B><BR>
<BR>
<BR>
CUMBERLAND PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ACKNOWLEDGED:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CUMBERLAND EMERGING TECHNOLOGIES, INC.

</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signature Page to Third Amendment to Second Amended and Restated Loan Agreement<BR>
(Cumberland Pharmaceuticals, Inc.) dated April&nbsp;6, 2008&#093;
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>BANK:</B><BR>
<BR>
BANK OF AMERICA, N.A.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Suzanne B. Smith
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Suzanne B. Smith&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Senior Vice President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21.1
<SEQUENCE>6
<FILENAME>g06286b1exv10w21w1.htm
<DESCRIPTION>EX-10.21.1 FIRST AMENDMENT TO OFFICE LEASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.21.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.21.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FIRST AMENDMENT TO OFFICE LEASE AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (this &#147;<B><I>Amendment</I></B>&#148;) is entered into between <B>2525
WEST END, LLC</B>, a Delaware limited liability company (&#147;<B><I>Landlord</I></B>&#148;), and <B>CUMBERLAND PHARMACEUTICALS
INC.</B>, a Tennessee corporation (&#147;<B><I>Tenant</I></B>&#148;), with reference to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Nashville Hines Development, LLC (predecessor-in-interest to Landlord) and Tenant entered
into that certain Office Lease Agreement dated September&nbsp;10, 2005 (the &#147;<B><I>Lease</I></B>&#148;) currently covering
approximately 6,341 RSF on the ninth (9th) floor (the &#147;<B><I>Original Premises</I></B>&#148;) of 2525 West End Avenue,
Nashville, Tennessee (the &#147;<B><I>Building</I></B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;Landlord and Tenant now desire to amend the Lease as set forth below. Unless otherwise
expressly provided in this Amendment, capitalized terms used in this Amendment shall have the same
meanings as in the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which are acknowledged,
the parties agree as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. First Expansion Space</B>. Landlord leases to Tenant and Tenant leases from Landlord approximately
2,950 additional RSF (the &#147;<B><I>First Expansion Space</I></B>&#148;) known as Suite&nbsp;930 and located on the ninth
(9th) floor of the Building as shown on the attached <U><B>Exhibit &#147;A&#148;</B></U>, which is incorporated
into this Amendment for all purposes. The term &#147;<B><I>Premises</I></B>&#148; as used in the Lease means and includes
approximately 9,291 RSF, being the sum of the RSF of the Original Premises (6,341 RSF) and the
First Expansion Space. The lease of the First Expansion Space is subject to all of the terms and
conditions of the Lease currently in effect, except as modified in this Amendment. Tenant
acknowledges that it has no further expansion or preferential rights or options under the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. First Extension Period</B>. The Term of the Lease as it pertains to the First Expansion Space only
is extended for a period of five (5)&nbsp;years (the &#147;<B><I>First Extension Period</I></B>&#148;) commencing on the First
Expansion Space Commencement Date (defined below), and expiring on December&nbsp;31, 2015, for a total
term of approximately ninety-one (91)&nbsp;months. The expiration of the Term of the Lease at is
pertains to the Original Premises shall remain December&nbsp;31, 2010 and after such expiration, all
rights under the Lease pertaining to the Original Premises including, but not limited to, those
Parking Permits set forth in Section&nbsp;3.4(a) of the Lease, shall terminate. Tenant acknowledges that
it has no further extension or renewal rights or options under the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3. Base Rental</B>. Exhibit&nbsp;G to the Lease is deleted and replaced by the rent schedule attached
hereto as <U><B>Exhibit &#147;B&#148;</B></U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Additional Rent</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Commencing on the First Expansion Space Commencement Date and continuing through the expiration
of the original Term (i.e., December&nbsp;31, 2010), Tenant&#146;s Additional Rental payable under Section
2.3 of the Lease shall be increased to take the First Expansion Space into account and the Expense
Stop, with respect to the First Expansion Space only, refers to Landlord absorbing and being
responsible for paying Operating Expenses (as defined in the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lease) during any calendar year to the extent such Operating Expenses are less than Nine and 42/100
Dollars ($9.42) per square foot of space in the Building leased to rent paying tenants as such term
is used in Section&nbsp;2.3(c) of the Lease.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Commencing on January&nbsp;1, 2011 and continuing through the expiration of the First Extension
Period, Tenant&#146;s Additional Rental payable under Section&nbsp;2.3 of the Lease shall be decreased so as
to omit the Original Premises.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Condition of the First Expansion Space</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Tenant accepts the First Expansion Space in its &#147;as-is&#148; condition. Tenant acknowledges
that Landlord has not undertaken to perform any modification, alteration or improvement to the
First Expansion Space. <FONT style="font-variant: SMALL-CAPS"><B>By taking possession of the First Expansion Space, Tenant waives</B>
</FONT><B>(i)</B><FONT style="font-variant: SMALL-CAPS"><B> any
claims due to defects in the First Expansion Space;
</B><U><B>and</B></U></FONT> <B>(ii) </B><FONT style="font-variant: SMALL-CAPS"><B>all
express and implied warranties of suitability, habitability and fitness for any particular
purpose</B></FONT><B>. </B>Tenant waives the right to terminate the Lease due to the condition of the First
Expansion Space.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The term &#147;<B><I>First Expansion Space Commencement Date</I></B>&#148; means the earlier of (i)&nbsp;June&nbsp;1, 2008,
and (ii)&nbsp;the date Tenant occupies the First Expansion Space. Landlord shall not be liable or
responsible for any claims, damages or liabilities incurred (or alleged) by Tenant due to any delay
in delivery of the First Expansion Space, nor shall such failure invalidate the Lease or extend the
First Extension Period. Upon determination, Landlord and Tenant, at the request of either, shall
execute an amendment to the Lease confirming the First Expansion Space Commencement Date, together
with corresponding adjustments to the schedule of Base Rental.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6. Parking</B>. In connection with the First Expansion Space, Landlord hereby agrees to make
available, or to cause the Garage Operator to make available, to Tenant (so long as Tenant shall
continue to lease the First Expansion Space) up to twelve (12)&nbsp;permits (&#147;<B><I>First Expansion Space
Permits</I></B>&#148;) to park in the Kensington Parking Facility upon the terms and conditions set forth in
Section&nbsp;3.4 of the Lease. Tenant shall pay as rental for the First Expansion Space Permits at the
rate charged from time to time by Landlord (or the Garage Operator), in its sole and absolute
discretion, plus any applicable taxes thereon. The current charge to Tenant for each First
Expansion Space Permit is $40.00 per month, plus any applicable taxes thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7. Improvement Allowance</B>. Tenant shall receive an improvement allowance in connection with the
First Expansion Space of $&#091;***&#093; per RSF in the First Expansion Space (the &#147;<B><I>First Expansion Space
Improvement Allowance</I></B>&#148;) to be paid by Landlord within thirty (30)&nbsp;days of the First Expansion Space
Commencement Date provided that Tenant is not then in default under the Lease. The First Expansion
Space Improvement Allowance may be used for any costs relating to the First Expansion Space.
However, Tenant shall not install any improvements which are not compatible with Landlord&#146;s plans
and specifications for the Building or which have not received prior written approval by Landlord
or Landlord&#146;s architect. Tenant agrees to comply with the terms of Section&nbsp;5.1 of the Lease with
respect to any Tenant work that is performed in the First Expansion Space.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8. Consent</B>. This Amendment is subject to, and conditioned upon, any required consent or approval
being unconditionally granted by Landlord&#146;s mortgagee(s). If any such consent shall be denied, or
granted subject to an unacceptable condition, this Amendment shall be null and void and the Lease
shall remain unchanged and in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9. No Broker</B>. Tenant represents and warrants that it has not been represented by any broker or
agent in connection with the execution of this Amendment. Tenant shall indemnify and hold harmless
Landlord and its designated property management, construction and marketing firms, and their
respective partners, members, affiliates and subsidiaries, and all of their respective officers,
directors, shareholders, employees, servants, partners, members, representatives, insurers and
agents from and against all claims (including costs of defense and investigation) of any broker or
agent or similar party claiming by, through or under Tenant in connection with this Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10. Time of the Essence</B>. Time is of the essence with respect to Tenant&#146;s execution and delivery to
Landlord of this Amendment. If Tenant fails to execute and deliver a signed copy of this Amendment
to Landlord by 5:00 p.m. (in the city in which the Premises is located) on May&nbsp;1, 2008, this
Amendment shall be deemed null and void and shall have no force or effect, unless otherwise agreed
in writing by Landlord. Landlord&#146;s acceptance, execution and return of this Amendment shall
constitute Landlord&#146;s agreement to waive Tenant&#146;s failure to meet such deadline.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>11. Miscellaneous</B>. This Amendment shall become effective only upon full execution and delivery of
this Amendment by Landlord and Tenant. This Amendment contains the parties&#146; entire agreement
regarding the subject matter covered by this Amendment, and supersedes all prior correspondence,
negotiations, and agreements, if any, whether oral or written, between the parties concerning such
subject matter. There are no contemporaneous oral agreements, and there are no representations or
warranties between the parties not contained in this Amendment. Except as modified by this
Amendment, the terms and provisions of the Lease shall remain in full force and effect, and the
Lease, as modified by this Amendment, shall be binding upon and shall inure to the benefit of the
parties hereto, their successors and permitted assigns.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Signatures to follow&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LANDLORD AND TENANT enter into this Amendment as of the Effective Date (below).
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="42%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="53%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>LANDLORD:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>2525 WEST END, LLC</B>, a Delaware limited liability company</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cash Flow Asset Management, L.P.,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">a Texas limited partnership, its sole manager</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="53%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CFAM GP, L.L.C.,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">a Texas limited liability company, its sole general partner</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="60%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">               /s/ John W. Emerson
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">John W. Emerson&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President<br>
Effective Date:  <u>April 25</u>, 2008&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>TENANT:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>CUMBERLAND PHARMACEUTICALS INC., </B>a Tennessee corporation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">               /s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">A.J. Kazimi&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT &#147;A&#148;</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FIRST EXPANSION SPACE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;to be attached&#093;</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->Ex. A-i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT &#147;B&#148;</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BASE RENTAL</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="13%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>FIRST</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>ORIGINAL</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>EXPANSION</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>PREMISES</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>SPACE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>FIRST</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>ORIGINAL</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>EXPANSION</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>ANNUAL</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>ANNUAL</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>PREMISES</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>SPACE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>BASE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>BASE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>RENTAL</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000"><B>RENTAL</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>MONTHLY</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>BASE</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" colspan="4" style="border-bottom: 1px solid #000000"><B>PERIOD</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>RATE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>RATE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>RSF</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>RSF</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>RENTAL</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/30/2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7/31/2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">8/1/2008</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12/31/2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/30/2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12/31/2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/31/2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2010</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12/31/2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/31/2011</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/31/2012</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2012</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/31/2013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2013</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/31/2014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2014</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5/31/2015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6/1/2015</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12/31/2015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->Ex. B-i<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24.1
<SEQUENCE>7
<FILENAME>g06286b1exv10w24w1.htm
<DESCRIPTION>EX-10.24.1 SECOND AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.24.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.24.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>SECOND AMENDMENT TO</B></U><BR>
<U><B>AMENDED AND RESTATED LEASE AGREEMENT</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>THIS SECOND AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT </B>(the &#147;<U>Amendment</U>&#148;)
is made and entered into to be effective as of the 9<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of January, 2006 (the
&#147;<U>Effective Date</U>&#148;), by and between <B>THE GATEWAY TO NASHVILLE, L.L.C., </B>a Tennessee
limited liability company, with its principal office and place of business in Nashville,
Tennessee (&#147;<U>Landlord</U>&#148;), and <B>CUMBERLAND EMERGING TECHNOLOGIES, INC., </B>a Tennessee
corporation, with its principal office and place of business in Nashville, Tennessee
(&#147;<U>Tenant</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WITNESSETH:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS, </B>pursuant to that certain Amended and Restated Lease Agreement made by and
between Landlord and Tenant dated November&nbsp;11, 2004, as amended by that First Amendment to
Amended and Restated Lease Agreement dated as of August&nbsp;23, 2005 (as amended, the
&#147;<U>Lease</U>&#148;), Landlord leased and demised to Tenant, and Tenant leased from Landlord, the
Premises, consisting of the Original Premises and the New Premises; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>, Landlord and Tenant desire to set forth the Acceptance Date for the New
Premises; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>WHEREAS</B>,
Landlord and Tenant desire to amend the Lease to reflect the foregoing
agreements and otherwise, pursuant to the terms and conditions hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>NOW</B>,
<B>THEREFORE</B>, for and in consideration of the foregoing premises and the mutual
covenants, terms and conditions recited hereinafter, and for such other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, Landlord and
Tenant hereby amend the Lease as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. Capitalized terms used herein shall have the meaning given in the Lease unless otherwise
defined herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. <U>Section&nbsp;4(d)</U> of the Lease is amended to provide that the Acceptance Date shall be
January&nbsp;9, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. <U>Section&nbsp;2</U> of the Lease is amended to the extent necessary to provide that the term
of the Lease shall terminate on July&nbsp;8, 2011, subject to any Extension Term, unless earlier
terminated pursuant to the terms of the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. Except as herein modified and amended, the terms and conditions of the Lease
shall remain in full force and effect.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;SIGNATURES APPEAR ON FOLLOWING PAGE&#093;</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, the parties hereto have executed this Amendment to be effective as
of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>LANDLORD:</B><BR>
<BR>
<BR>
THE GATEWAY TO NASHVILLE, L.L.C.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/
Zachary B. Liff
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its: Chief Manager                               &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>TENANT:</B><BR>
<BR>
<BR>
CUMBERLAND EMERGING<BR>
TECHNOLOGIES, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ A.J. Kazimi
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Its: C.E.O.                                       &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>8
<FILENAME>g06286b1exv10w25.htm
<DESCRIPTION>EX-10.25 MANUFACTURING AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.25 MANUFACTURING AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 10.25</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 1 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MANUFACTURING AGREEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Manufacturing Agreement is effective as of <B>February&nbsp;6, 2008 </B>(&#147;Effective Date&#148;) by and among
<B>Bayer HealthCare, LLC</B>, a Delaware limited liability company with an office at 12707 West Shawnee
Mission Parkway, Shawnee, KS 66216 (hereinafter &#147;Bayer&#148;), and Cumberland Pharmaceuticals Inc., a
Tennessee corporation, organized under the laws of Tennessee, having its principal place of
business at Nashville, TN (hereinafter &#147;Cumberland&#148;) and their products described herein.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">WITNESSETH:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Cumberland is a manufacturer and developer of healthcare products and is the owner of
all rights to certain proprietary technical information, patents, and patent applications relating
to its products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Bayer is a manufacturer of healthcare products and possesses the requisite expertise,
personnel, and facilities for the manufacture and supply of injectable products and is willing to
manufacture for and supply to Cumberland such products as specified in <B>Exhibit&nbsp;1 </B>and to perform
such services described in <B>Exhibit&nbsp;1 </B>(One Time Costs to Cumberland).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Cumberland wishes to engage Bayer and Bayer desires to accept such engagement to
perform at Bayer&#146;s facilities certain manufacturing, packaging, labeling, and/or laboratory
services on behalf of and for the benefit of Cumberland with respect to production of its Product
(the &#147; Manufacturing Services&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the premises, the mutual covenants herein contained, and
other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>DEFINITIONS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For the purposes of this Agreement, the following terms shall have the meanings set forth
below:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Active Pharmaceutical Ingredient&#148; shall mean the pharmacologically active agent for the
manufacture of a Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Affiliate &#151; Any person or business entity which directly or indirectly controls, is
controlled by, or is under common control with a party to this Agreement. In this Agreement,
an Affiliate of Cumberland will include the distributor of Products. A business entity shall
be deemed to &#147;control&#148; another business entity, if it owns directly or indirectly, fifty
percent (50%) or more of the outstanding voting securities, capital stock, or other comparable
equity or ownership interest of such business entity, or exercises equivalent influence over
such entity. If the laws of the jurisdiction in which such entity operates prohibit ownership
by a party of fifty percent (50%) or more, &#147;control&#148; shall be deemed to exist at the maximum
level of ownership allowed by such jurisdiction.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Components &#151; All materials (including, Active Pharmaceutical Ingredient, packaging and
shipping materials), whether produced by Bayer or procured from Cumberland or a third party
vendor, which are incorporated into the Product by Bayer in the performance of its
Manufacturing Services.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland Components means those &#147;Components&#148; which are furnished by Cumberland or by a
third party vendor on behalf of Cumberland.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Drug Master File shall mean the Drug Master File for manufacturing an Active Latent
Pharmaceutical Ingredient filed with the United States Food &#038; Drug Administration, and the
equivalent filing with the governing health authority of any other country.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Latent Defect &#151; Any instance where all or portion of batch of a Product fails to
conform to the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 2 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">applicable Specifications, Legal Requirements or is otherwise defective or fails to
conform to the warranties given by Bayer herein, and such failure would not be
discoverable upon reasonable physical inspection performed pursuant to Bayer&#146;s standard
operating procedures of such Product. Product containing Latent Defects may be rejected in
accordance with the procedures set forth in Sections&nbsp;2.5 and 2.6 hereof.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Legal Requirements &#151; Any present and future national, state, or local law (whether under
statute, rule, regulation, or otherwise), including, without limitation, US Federal Food, Drug
and Cosmetic Act of 1934, and the regulations promulgated there under, as the same may be
amended from time to time (the &#147;Act&#148;); requirements under permits, orders, decrees, judgments,
or directives; and requirements of a Regulatory Agency and any other applicable government
authorities, including without limitation Good Manufacturing Practices as promulgated by the
United States Food and Drug Administration and specified in the U.S. Code of Federal
Regulations Parts 210 and 211, as amended from time to time. The determinations of Cumberland
regarding Legal Requirements shall be dispositive for purposes of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Process &#151; The practices and procedures to be followed in the manufacturing, labeling,
packaging, storage, and transport of the Product, as agreed to by the parties.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Product(s) &#151; The final Product(s) that is (are)&nbsp;delivered by Bayer to Cumberland or
Cumberland&#146;s designee after all Manufacturing Services have been completed by Bayer as
specified in <B>Exhibit&nbsp;1</B>. Additional Products may be added to Exhibit&nbsp;1 by mutual written
agreement signed by both parties.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Quality Agreement &#151; The certain Quality Agreement executed by the parties hereto in
connection with this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Regulatory Agency &#151; A regulatory authority having jurisdiction over the manufacture or sale
of a Product.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Specifications &#151; The specifications set forth in the Quality Agreement, as may be amended by
Cumberland after written notice to Bayer, from time to time.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>DESCRIPTION OF SERVICES</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer will perform all Manufacturing Services described in the attached <B>Exhibit&nbsp;1 </B>in
accordance with the terms and conditions of this Agreement and the Quality Agreement, as well
as in accordance with any manufacturing procedure adopted by written agreement of the parties
hereto after production of pilot batches (a &#147;Master Batch Record&#148;), as applicable, and with
all Legal Requirements. Bayer shall perform the Manufacturing Services on a timely basis so as
to meet the volume requirements of Cumberland as set forth pursuant to Article&nbsp;3 below.
Without limiting the generality of the foregoing, Cumberland will, at its sole cost and
expense, obtain and maintain all Drug Master Files, licenses, permits, certifications, and
approvals from any and all Regulatory Agencies which are or may become necessary for the
lawful performance of the Manufacturing Services. Bayer shall not make any change whatsoever
in the manufacturing facilities, equipment, processes, testing procedures, validation
procedures, Specifications, materials or Components, Cumberland Components, or documentation
systems used to perform the Manufacturing Services if such change would cause any variation in
the quality or merchantability or affect any Regulatory Agency submission, license, permit,
certification, or approval required for the performance of the Manufacturing Services, either
foreign or domestic, without the prior written consent of Cumberland.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer shall use commercially reasonable efforts to meet Cumberland&#146;s requested delivery
dates, which shall be not more than 90&nbsp;days after Bayer&#146;s receipt of Cumberland&#146;s purchase
orders. Requested delivery dates may be changed only by mutual written agreement. In the event
that Bayer has reason to believe that it will be unable to meet the agreed upon delivery
dates, Bayer will notify Cumberland promptly and state the reason(s) for the delay.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 3 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">In addition to all other available remedies available, Cumberland may procure products from
an alternate source in order to meet delivery dates that are unattainable by Bayer. Bayer
shall not be responsible for delays caused by carriers selected by Cumberland.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer warrants that all Products delivered to Cumberland or Cumberland&#146;s designee pursuant to
this Agreement will conform to the Specifications at the time of delivery and will comply with
all Legal Requirements in effect at the time of such delivery and shall not be adulterated or
misbranded within the meaning of the Act. Bayer agrees to promptly notify Cumberland in
writing of any defects in the Products or of any defects as they relate to the manufacture
and/or supply of the Products. Bayer shall notify Cumberland and their designee within three
(3)&nbsp;business days of learning of any failure of any batch of Products to meet the standards
provided by Cumberland pursuant to this Agreement or as otherwise set forth in the Quality
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>EXCEPT AS PROVIDED IN THIS SECTION 2.3, BAYER MAKES NO REPRESENTATION OR WARRANTY OF ANY
KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE SUPPLY OF THE PRODUCTS, ITS MERCHANTABILITY,
OR ITS FITNESS FOR A PATICULAR PURPOSE. BAYER SHALL NOT BE LIABLE FOR ANY CONSEQUENTIAL
DAMAGES OR LOSS OF ANTICIPATED PROFITS SUSTAINED BY CUMBERLAND.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Bayer notifies Cumberland of the non-conformance of Products and Bayer is unable to
provide Products that conform to the Specifications and comply with all applicable Legal
Requirements within ninety <B>(90) </B>days of such notice, contingent on supply of components
including new materials, Cumberland may, without limiting any remedies available to it,
discontinue the purchase of non-conforming Products from Bayer, without any further obligation
to Bayer, and purchase replacement products from an alternate manufacturer until such time as
Bayer is able to resume production of Products with Cumberland&#146;s approval in accordance with
the Specifications and applicable Legal Requirements, subject to depletion of any inventory on
hand that was purchased or is to be delivered pursuant to contractual commitments to purchase
such Product from the alternate source or sources. In the event Cumberland orders Product from
an alternate supplier as provided herein, Bayer shall, at Cumberland&#146;s request, provide all
reasonable assistance requested by Cumberland to qualify an alternate supplier and supply such
alternate supplier with the necessary Active Pharmaceutical Ingredient at Bayer&#146;s actual
manufacturing or acquisition cost. Bayer shall reimburse Cumberland on demand for the
difference between the cost of obtaining such substitute Product (plus any commercially
reasonable charges, expenses or commissions incurred by Cumberland in connection with
effecting cover, and any other reasonable expenses incident to such failure), less the price
which would have been due to Bayer for the like quantity of Product if supplied by Bayer
hereunder.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer shall obtain and maintain all equipment required to fulfill its obligations under this
Agreement consistent with applicable Good Manufacturing Practices. All Products are subject to
Cumberland&#146;s inspection prior to acceptance. Cumberland shall have fifteen (15)&nbsp;business days
following the receipt of Products to inspect the Products for the purposes of rejecting all or
a portion of such Products if all or a portion of the Products (i)&nbsp;fails to conform to the
Specifications, (ii)&nbsp;shall not have been manufactured in compliance with then applicable Bayer
requirements, or (iii)&nbsp;otherwise fails to conform to the warranties set forth in this
Agreement; provided, however, that in the event there is a Latent Defect in the Products,
Cumberland shall have the right to reject all or a portion of the Products that contain such
Latent Defects following discovery thereof, subject to the requirements of Section&nbsp;2.6 below.
Upon detection of any defect, Cumberland shall give notice to Bayer specifying the manner in
which all or part of such shipments fails to meet the foregoing requirements and may withhold
payment for that shipment or portion thereof which it has rejected.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon detection of any material defect, including a Latent Defect, Cumberland shall give
notice within three (3)&nbsp;business days to Bayer specifying the manner in which all or part of
such shipment fails to meet the foregoing requirements and may withhold payment for that
shipment or portion thereof which it has rightfully rejected. Bayer shall have fifteen (15)
days within which to cure such defect. In the event that Cumberland rightfully rejects any
products</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 4 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">and payment has already been made for such Products, Cumberland shall be entitled to recoup
the payment amount if Bayer is unable to cure such defect within the fifteen (15)&nbsp;day
period. In the event of any dispute between the parties as to whether Cumberland has
rightfully rejected any products, the parties shall submit such dispute to a mutually
agreed to independent laboratory. The determination by such laboratory shall be final and
binding and the costs therefor shall be borne by the non-prevailing party.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer shall provide all documents and updates with regard to the Product which are required
by any Regulatory Agency, and shall submit to all inquiries and inspections by any such
Regulatory Agency. All documents provided by Bayer to any Regulatory Agency with regard to the
Product shall be provided to Cumberland in advance, if feasible, and in any case within two
(2)&nbsp;business days after such documents are provided to any Regulatory Agency. Bayer shall
promptly notify Cumberland of all scheduled inspections of Bayer&#146;s facilities or records by a
Regulatory Agency concerning the Product, whereupon Cumberland shall have the right to be
present for such inspection. Bayer shall provide any and all written and verbal communications
from any Regulatory Agency pertaining to or affecting the Active Pharmaceutical Ingredient or
the Product no more than two (2)&nbsp;business days after Bayer receives such communications,
including any summary or other record of inspectional observations or findings and all related
communications by Bayer with such Regulatory Authority. Cumberland shall have the right to
audit Bayer&#146;s facilities or records during regular business hours on not less than seven (7)
days prior written notice by the Cumberland. Such audit shall be limited to facilities and
records pertaining to the Product.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Nothing in this Agreement shall prevent Cumberland or its Affiliates from manufacturing
Product for amounts in excess of the orders for Product placed with Bayer in accordance with
this Agreement. Further, Cumberland or its Affiliates shall not be prevented from qualifying
and using sources of supply other than Bayer and securing Manufacturing Services or Product
from those other sources, as long as such activities do not interfere with the requirements of
this Agreement. In no event, however, shall Bayer disclose to any third party Cumberland
Confidential Information (as defined in Article&nbsp;7 below) belonging to Cumberland, it being
understood that any information contained in the Master Batch Record does constitute
Confidential Information belonging to Cumberland.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUPPLY OF PRODUCT</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer and Cumberland shall cooperate in estimating and scheduling the performance of the
Manufacturing Services and the delivery of Product to Cumberland.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Within &#091;***&#093; days after execution of this Agreement and thereafter monthly within &#091;***&#093; days
of that respective month, Cumberland shall provide non-binding forecasts for Product to Bayer
by month for the immediately succeeding twelve (12)&nbsp;month period.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland shall issue purchase orders setting forth the quantities and delivery dates at
least &#091;***&#093; days in advance of the requested delivery date. Bayer shall be obligated to
formulate and supply Product in accordance with quantities and delivery dates requested in the
firm orders placed by Cumberland, Bayer will procure sufficient bulk quantities to produce
product prior to or at the time a purchase order is issued.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer agrees to give timely notice to Cumberland of any maintenance, plant modifications, or
other event that may affect Bayer&#146;s capacity or otherwise affect its ability to meet
forecasted quantities with sufficient advance notice to permit Cumberland to order additional
Product to meet its requirements for such periods. Bayer shall use commercially reasonable
efforts to assure that adequate capacity is available to fulfill future requirements of
Cumberland.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer shall use Cumberland designated carriers. In the event that a Cumberland designated
carrier is not available, Bayer may use a qualified carrier of its choice, with prior written
approval from Cumberland. Products shall be packed and shipped in accordance with Cumberland&#146;s
instructions, good commercial practices and in compliance with all Legal
Requirements. Each shipment of Product shall be clearly marked as per Cumberland&#146;s</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 5 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">requirements. Shipment will be FOB Shawnee, Kansas. Number of shipments are limited to no
more than three (3)&nbsp;locations per batch quantity.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither Bayer nor any Affiliate thereof will sell, give away, or deleiver to any other
person, firm, or corporation any form of Product for indications currently approved as of
the Effective Date while this Agreement is effective and for two years after the termination
of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FEES</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration for the services to be performed by Bayer, Cumberland will pay Bayer a
fee per unit of Product delivered to and accepted by Cumberland. The quantity and fee per
unit to be paid by Cumberland shall be as specified in the attached <B>Exhibit&nbsp;2</B>. The quantity
and one-time costs to be paid by Cumberland shall be as spedified in the attached Exhibit
1. Regarding definition of Cumberland as described on page 1, responsibility of payment
solely resides with Cumberland.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any change in the Specifications requested by Cumberland, Cumberland shall
reimburse Bayer for costs actually incurred by Bayer in connection with such change,
including without limitation, one-time development costs specifically related to such
change, costs of obsolescence of raw materials, goods-in-process, packaging material
components and supplies (bulk containers and labels), and finished goods, which shall be
valued at the cost incurred by Bayer, except that finished goods inventory will be valued
at the Price pursuant to <B>Exhibit&nbsp;2 </B>of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All fees shall be determined on the basis of Product being delivered F.O.B. Cumberland&#146;s
third party packager &#091;plant location&#093; and may be subject to change by mutual agreement of
the parties hereto after the third anniversary of the Effective Date.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fees payable by Cumberland to Bayer under this Agreement shall be due and
payable &#091;***&#093; days after the receipt of Bayer&#146;s invoice and all required
accompanying documentation to be supplied by Bayer and acceptance of the
delivered Product by Cumberland. If Cumberland does not timely issue a
notice of non-conformity of the delivered Product to Bayer pursuant
to the Quality Agreement, such delivered Product shall be
considered accepted by Cumberland. Bayer will issue its invoice
only at such time as Product</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 6 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">has been released pursuant to the terms and conditions of the Quality Agreement, and
only at such time as the documents specified in the Quality Agreement have been
delivered by Bayer to Cumberland. Past due invoices are subject to a late charge at
the maximum rate of 18% per annum or a minimum charge of $2.00, whichever is greater.
A 15-day grace period will apply.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ADVERSE EVENTS/RECALLS/WITHDRAWALS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer shall inform Cumberland immediately of any important information relating to the
activity, side effects, toxicity, and/or safety of the Product that becomes known to Bayer
during the term of this Agreement. Furthermore, Bayer shall inform Cumberland immediately of
any defects in the manufacturing processes for the Product that becomes known to Bayer during
the term of this Agreement. Bayer agrees to carry out its obligations with respect to the
reporting of adverse drug reactions as described in the attached <B>Exhibit&nbsp;3</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland shall inform Bayer immediately of any important information relating to the
activity, side effects, toxicity, and/or safety of the Product that becomes known to
Cumberland during the term of this Agreement and that is relevant to the performance of the
Manufacturing Services by Bayer. Cumberland agrees to carry out its obligation with respect to
the reporting of adverse drug reactions as described in the attached <B>Exhibit&nbsp;3</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that a recall or market withdrawal of a Product is required by a governmental
agency or authority of competent jurisdiction, or if a recall or market withdrawal of Product
is deemed advisable by Cumberland in its sole discretion, such recall shall be implemented and
administered in a manner which is appropriate and reasonable under the circumstances and in
conformity with any requests or orders of local Regulatory Agencies, as well as accepted trade
practices. The costs and expenses associated with the recalling or withdrawing a Product shall
be paid by Cumberland, provided, however, that if the recall or withdrawal is related to a
failure of Bayer to follow the Specifications or to any act or omission of Bayer in its
performance of the Manufacturing Services, the costs of the recall solely related to Bayer&#146;s
failure in performance shall be borne by Bayer. In the event that a Product is recalled or
that Cumberland is required to disseminate information relating to a Product covered by this
Agreement, Cumberland shall so notify Bayer within a reasonable time so as to enable Bayer to
provide Cumberland with such assistance in connection with such recall as may reasonably be
requested by Cumberland. Bayer will comply with all such reasonable requests from Cumberland.
Cumberland shall handle exclusively the organization and implementation of all recalls of the
Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INDEMNIFICATION</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer shall indemnify, defend and hold Cumberland, its Affiliates, and their respective
principals, directors, officers, employees, representatives and agents harmless from and
against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys&#146; and consultants&#146; fees and amounts paid in settlement with the consent of Bayer,
which consent shall not be unreasonably withheld or delayed) arising from any claim, lawsuit,
or other action made, brought, or threatened against Cumberland as a result of (i)&nbsp;a breach or
default of this Agreement or the Quality Agreement by Bayer, or (ii)&nbsp;any act or omission by
Bayer in the performance of the Manufacturing Services, except to the extent such claim,
lawsuit, or other action results from any act or omission by Cumberland relating to its
performance of this Agreement. Cumberland shall inform Bayer of any such claim, lawsuit, or
other action to which this Paragraph&nbsp;6.1 applies within a reasonable time after receiving
notice thereof. Cumberland shall have the right to retain, at its own expense, its own legal
counsel to defend it with respect to such claim, lawsuit, or other action and to participate
in the defense thereof, provided, however, that to the extent Bayer is obligated to indemnify
Cumberland, Bayer shall have control of the defense of the action.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland shall indemnify, defend and hold Bayer, its Affiliates, and their respective
principals, directors, officers, employees, representatives and agents harmless from
and against any and all losses, damages, liabilities, costs and expenses (including reasonable</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 7 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">attorneys&#146; and consultants&#146; fees and amounts paid in settlement with the consent of
Cumberland, which consent shall not be unreasonably withheld or delayed) arising from any
claim, lawsuit, or other action made, brought, or threatened against Bayer as a result of
(i)&nbsp;a breach or default of this Agreement or the Quality Agreement by Cumberland, or (ii)
the sale, use, or distribution of the Product by Cumberland, except to the extent such
claim, lawsuit, or other action results from any act or omission by Bayer in the performance
of the Manufacturing Services specified herein. Bayer shall inform Cumberland of any such
claim, lawsuit, or other action to which this Paragraph&nbsp;6.2 applies within a reasonable time
after receiving notice thereof. Bayer shall have the right to retain, at its own expense,
its own legal counsel to defend it with respect to such claim, lawsuit, or other action and
to participate in defense thereof; provided, however, that to the extent Cumberland is
obligated to indemnify Bayer, Cumberland shall have control of the defense of such action.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer or Cumberland, as the case may be, will respond to all reasonable requests from the
other to assist in the disposition of any claim, lawsuit, or other action to which Paragraphs
6.1 and/or 6.2 apply.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Title and risk of loss to the the in-process and released Product shall remain with Bayer
while such Product is in the possession of Bayer.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CONFIDENTIALITY</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each party may from time to time provide to the other party information (hereinafter
&#147;Confidential Information&#148;). For purposes of this Agreement, Confidential Information shall
not include:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information which was known to the receiving party prior to receipt from the
disclosing party, as evidenced by written records;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information which was in the public domain or generally known to the trade at
the time of receipt from the disclosing party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information which enters the public domain or becomes generally known to the
trade through no fault of the receiving party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information which is disclosed to the receiving party by a third party who is
not under an obligation of confidentiality to the disclosing party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information which is independently developed by the receiving party without use
of the disclosing party&#146;s Confidential Information, as evidenced by written records; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information which is required to be disclosed by law, regulatory,
administrative or judicial order, provide that the receiving party has provided the
disclosing party with sufficient advance notice or such disclosure to enable the
disclosing party to seek to restrict the public disclosure of such Confidential
Information.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each party&#146;s Confidential Information shall be kept confidential by the other party and shall
not be disclosed by such other party for a period that is five (5)&nbsp;years from the expiration
or termination of this Agreement. Such Confidential Information shall not be disclosed by such
other party other than to its officers, employees, and agents who are engaged in its
operations relating to the Product and who have the need to know such Confidential Information
for purposes of meeting its obligations under this Agreement and the Quality Agreement. The
receiving party will only use Confidential Information of the disclosing party in the
furtherance of the purposes of this Agreement. Either party may use a discloser&#146;s Confidential
Information for the purpose of obtaining and maintaining approvals of a Regulatory Agency or
to otherwise meet Legal Requirements with respect to Product. Notwithstanding the foregoing,
Confidential Information may be disclosed if it is required to be disclosed in
compliance withapplicable laws or regulations, subpoena, court order, or order of such
other governmental or regulatory agency having competent jurisdiction; or
either party reasonably believes that it is necessary to disclose Confidential Information
in connection with any action, suit, or proceeding before any court or any governmental or
other</TD>
</TR>



</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 8 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">regulatory agency or body, or any arbitral panel; or any audit or investigation brought by
any governmental or other regulatory agency or body; or the assertion of any claim against
any insurer or other third party; provided, however, that reasonable measures shall be taken
to assure confidential treatment of such information. Each party recognizes that any
violation of this confidentiality provision would cause the other irreparable harm and
agrees that the other party shall be entitled, in addition to any other right or remedy it
may have, at law or in equity, to an injunction without the posting of any bond or other
security, enjoining the disclosing party, its affiliates and their respective officers,
directors, employees, and agents from any violation or potential violation of this Article
7.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All new techniques, discoveries, inventions, processes, and know-how (each a &#147;New
Development&#148;) relating to the Product which are developed by Bayer during the performance of
this Agreement and which result from access to Cumberland or its Affiliates Confidential
Information shall be the property of Cumberland or its Affiliates. Cumberland or its
Affiliates shall grant to Bayer a nontransferable, nonexclusive, royalty-free, worldwide,
perpetual license to make, use, sell, and offer to sell such New Development(s). This
licensing shall expire upon termination of this agreement. Notwithstanding the grant of such
license, Bayer shall not use such New Development(s) of Cumberland or its Affiliates
Confidential Information to compete, or assist third parties in competing, directly or
indirectly, with Cumberland or its Affiliates in the use or sale of the Product Bayer agrees
to cooperate in the filing and prosecution of all New Development(s) patent applications filed
by Cumberland or its Affiliates, but Cumberland or its Affiliates shall bear all associated
expenses. As to New Development(s) which may be developed by Bayer during the performance of
this Agreement which relate to the Product but which do not result from access to Confidential
Information of Cumberland or its Affiliates, Bayer grants to Cumberland or its Affiliates a
nontransferable, royalty-free, irrevocable, worldwide, nonexclusive license to make, have
made, sell, or offer to sell the New Development(s) in connection with the Product.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither party shall use the other&#146;s name or refer to it directly or indirectly in an
advertisement, news release, or release to any professional or trade publication without
written approval from such party. The parties expressly consent to such disclosure in filings
with the Securities and Exchange Commission and the Food and Drug Administration and
analogous agencies in other countries. Cumberland or its Affiliates and Bayer agree that the
existence and contents of this Agreement shall be maintained in confidence and not disclosed
or used for any purpose without the prior written consent of each party, except as otherwise
provided herein or required by law.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The provisions of this Article&nbsp;7 shall survive termination of this Agreement for any reason.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>TERM</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall become effective on the Effective Date and, except as otherwise provided
herein, shall be in effect for an initial term of &#091;***&#093; years. Thereafter, so long as this
Agreement is in force, it shall be automatically renewed for additional terms of one (1)&nbsp;year,
unless one party elects to terminate this Agreement by notice thereof to the other party in
writing at least six (6)&nbsp;months prior to expiration of the then existing term.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Either party may terminate this Agreement for a material breach by the other party by giving
the breaching party written notice, specifying the breach relied on, and giving the breaching
party thirty (30)&nbsp;days to cure such breach. If the breaching party has not cured the default
at the end of the thirty (30)&nbsp;day period, then, upon notice thereof to the breaching party by
the other, this Agreement shall terminate. Termination for breach will have no effect on
obligations that have accrued up to the effective date of such termination or any obligations
that, by their terms, survive the termination of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland shall have the right to terminate this Agreement upon thirty (30)&nbsp;days notice in
the event of a change of the site of manufacture of any Products to any site that has
not been approved by Cumberland. Such approval shall not be unreasonably withheld.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland may terminate this Agreement in the event of a change in control of Bayer. A</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 9 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">change in control shall mean the occurrence of either of the following events: (i)&nbsp;any
&#147;person&#148; or &#147;group&#148; (as such terms are defined in Sections 13(d) and 14(d) of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), which is a competitor to Cumberland,
is or becomes the &#147;beneficial owner&#148; (as such term is used in Rule&nbsp;13d-3 under the Exchange
Act) of more than fifty percent (50%) of the total voting power of Bayer (whether by
acquisition of stock, merger, or otherwise) or (ii)&nbsp;Bayer sells all or substantially all of
the assets utilized in connection with this Agreement. Any termination pursuant to this
Paragraph&nbsp;8.4 shall be effective on the thirtieth (30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day following the date
on which such written notice is given.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any proceedings, voluntary or involuntary, in bankruptcy or insolvency, by or
against Cumberland or Bayer, or the appointment with or without the party&#146;s consent of a
receiver for either party, or the other party makes or seeks to make a general assignment for
the benefit of its creditors or applies for or consents to the appointment of a trustee or
custodian for it or a substantial part of its property, and such situation is not cured within
thirty (30)&nbsp;days from its occurrence, the other party shall be entitled to terminate this
Agreement upon giving written notice.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of termination pursuant to this Section&nbsp;8, the parties will cooperate in the
orderly transition of supply so as not to cause inconvenience to either party. Should
termination in accordance with this section 8 be initiated by Bayer, Bayer shall notify
Cumberland in writing of its desire to so terminate; provided, however, that termination by
Bayer shall not be effective until Cumberland has located and arranged for continuation of any
ongoing Manufacturing Services with another product manufacturer, so long as such termination
procedure shall not extend beyond eighteen (18)&nbsp;months from Bayer&#146;s written notice of
termination to Cumberland. In the event Bayer terminates this Agreement as provided
hereunder, Bayer shall, at Cumberland&#146;s request, provide commercially reasonable assistance
requested by Cumberland to qualify an alternate supplier. The parties will cooperate during
such period to continue the Manufacturing Services on the basis set forth in this Agreement.
In the event of notice of such early termination by Cumberland, Bayer shall perform such
functions reasonably necessary or required in connection with the orderly wind-down of the
Manufacturing Services as required by the terms of this Agreement and/or any Legal
Requirements, including any applicable Regulatory Agency regulations, and Cumberland shall pay
Bayer for the Manufacturing Services performed, under the terms and conditions of this
Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland shall also have the right to terminate this Agreement upon thirty (30)&nbsp;days
written notice to Bayer in the event a Regulatory Agency does not approve the Product for
marketing; or a Regulatory Agency withdraws marketing approval; or Cumberland otherwise
terminates the commercial sale of Product. If Cumberland terminates pursuant to this provision
or a Regulatory Agency does not approve the Product for marketing or withdraws marketing
approval, Cumberland shall reimburse Bayer for any purchases of Components used in the
performance of the Manufacturing Services which cannot be cancelled, as well as associated
documented out-of-pocket costs incurred by Bayer in performances of Manufacturing Services.
The reimbursement shall be made within thirty (30)&nbsp;days following receipt by Cumberland of an
invoice itemizing the costs of such Components and Manufacturing Services. Bayer agrees to
transfer to Cumberland any Components paid for by Cumberland under this provision. Termination
under this provision shall have no effect on payment obligations that otherwise may have
accrued up to the effective date of termination.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>COMPLIANCE WITH APPLICABLE LAW</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the term of this Agreement, Bayer and all its subcontractors, employees, agents,
representatives, and invitees shall comply with all applicable laws, governmental regulations,
rules, requirements, ordinances, and other requirements of federal, state, and local
authorities. Bayer is not authorized to take any action in the name of or otherwise on behalf
of Cumberland which would violate any of the foregoing.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer represents and warrants that at the time of submission of its proposal for the
performance of the Services, it was and remains properly licensed and qualified to do business
in all jurisdictions in which the Services are to be performed, and agrees that it will
maintain such licenses and qualifications and acquire any additional licenses and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 10 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">qualifications as may be thereafter required by law or otherwise. If any licenses required
by law are revoked or altered, Bayer shall immediately notify Cumberland.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer represents and warrants that it has not and has never been, nor has any of its
employees, agents, or subcontractors who may provide services under this Agreement ever been
debarred or, to the best of its knowledge, (i)&nbsp;convicted of a crime for which a person or
entity can be debarred, under Section 306(a) or 306(b) of the United States Generic Drug
Enforcement Act of 1992 or under 42 USC Section&nbsp;1320a-7, or (ii)&nbsp;sanctioned by, suspended,
excluded, or otherwise ineligible to participate in any federal health care program, including
Medicare and Medicaid, or in any federal procurement or non-procurement programs.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer agrees:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to comply with the equal employment opportunity and affirmative action
provision of: (1)&nbsp;Executive Order 11246, as amended and U.S. Dept. of Labor
regulations issued pursuant thereto (41 CFR 60); (2)&nbsp;Section&nbsp;503 of the Rehabilitation
Act of 1973 (29 U.S.C. 793), as amended; and U.S. Dept. of Labor regulation issued
pursuant thereto (41 CFR 60-741), in contracts for $2500 or more; and (3)&nbsp;Section&nbsp;402
of the Vietnam Era Veterans Readjustment Assistance Act of 1974 (38 U.S.C. 2012), and
U.S. Dept. of Labor regulations pursuant thereto (41 CFR 60-250), in
contracts for $10,000 or more; Title VII of Civil Rights of 1964, 78 Stat. 253, as
amended, and regulations issued pursuant thereto.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INSURANCE</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each Party shall obtain and maintain insurance coverage against such
liability in limits provided in <B>Exhibit&nbsp;4</B>. Each Party stipulates that it will use
its best efforts such that the insurance will not be cancelled while this Agreement is
in effect without thirty (30)&nbsp;days prior written notice to the other Party. Each Party
shall maintain such insurance during the Term and thereafter for so long as it
customarily maintains insurance for itself for similar products and activities. Each
Party shall use its best efforts so that the other Party is named as an additional
insured under the Product Liability policy and shall provide the other Party proof of
such insurance upon request. Each party shall use its best efforts to provide
reasonable notice to the Party listed as additional insured on its Product Liability
Policy of any cancellation, termination, or change in such insurance, such prior
written notice to be no less than thirty (30)&nbsp;days of any such change. Each Party
shall obtain and maintain product liability insurance coverage against such liability
in limits provided in <B>Exhibit&nbsp;4</B>. Each Party stipulates that the insurance will not
be cancelled while this Agreement is in effect without thirty (30)&nbsp;days prior written
notice to the other Party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>MISCELLANEOUS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except as provided in Paragraph&nbsp;7.3, nothing in this Agreement will be deemed or construed as
providing either party any right, title, interest, or license in or under any intellectual
property right owned or controlled by the other party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Modifications and amendments to this Agreement and its Exhibits require the written consent
of both parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No waiver of any requirement of this Agreement, whether by conduct or otherwise, will be
effective unless in writing. The waiver in any one or more instances will not be deemed or
construed to be a further or continuing waiver of any such requirement or of any other
requirement of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The provisions of this Agreement shall be deemed separate. Accordingly, the invalidity,
illegality, or unenforceability of any particular provision of this Agreement shall not in any
way affect or impair the other provisions, and this Agreement shall be construed in all
respects as if such invalid, illegal, or unenforceable provision were omitted, except in cases
where such unenforceable provision is a basic requirement of any party or both parties to</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 11 of 23
</DIV>


<DIV align="left" style="margin-left: 4%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">enter into this Agreement.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any notice required or permitted to be given hereunder will be deemed sufficient if delivered
by hand or sent by overnight courier to the parties at the addresses set forth below, or such
other addresses as either party may designate. Notice will be deemed given when received.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">If to Bayer, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Dr.&nbsp;Detlef Mathes<BR>
VP of Operations<BR>
12707 West Shawnee Mission Parkway<BR>
Shawnee, KS 66216
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">with a courtesy copy, which shall not constitute notice hereunder, sent to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Cynthia Hughes-Coons<BR>
Assistant General Counsel<BR>
12707 West Shawnee Mission Parkway<BR>
Shawnee, KS 66216
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">If to Cumberland, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Cumberland Pharmaceuticals Inc.<BR>
2525 West End Avenue<BR>
Suite&nbsp;950<BR>
Nashville, TN 37203<BR>
Attn A.J. Kazimi
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">with a courtesy copy, which shall not constitute notice hereunder, sent to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Adams and Reese LLP<BR>
424 Church Street<BR>
Suite&nbsp;2800<BR>
Nashville, TN 37219<BR>
Attn. Martin S. Brown, Jr.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither party will assign this Agreement, or subcontract any of its obligations hereunder, to
any other person or entity other than to one or more Affiliates, without the prior written
consent of the other party, which consent will not be unreasonably withheld; however, in the
event of any assignment or subcontract, the party effecting such assignment or subcontract
shall guarantee the performance of the assignee or subcontractor in a form satisfactory to the
other party. Notwithstanding the foregoing, either party may, without such written consent,
assign this Agreement, and its rights and objections hereunder, in connection with the
transfer or sale of all or substantially all of its business or part of its business to which
this Agreement pertains, or in the event of its merger or consolidation or change in control
or similar transaction, provided the permitted assignee shall have assumed all obligations of
the assignor under this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement will be binding upon and inure to the benefit of the permitted successors or
permitted assigns of Bayer and Cumberland.</TD>
</TR>

<TR>
    <TD width="1%">&nbsp;</TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be construed, interpreted, and applied in accordance with the laws of
the State of New York ,without reference to it conflict of laws provisions.
</TD>
</TR>

</TABLE>
</DIV>



<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Product labeling (primary, secondary, and insert) and filings with a Regulatory Agency may
indicate that the Product has been manufactured for Cumberland by Bayer. Except when Legal
Requirements mandate or when necessary to seek the approval of any Regulatory Agency,</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 12 of 23
</DIV>


<DIV align="left" style="margin-left: 5%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">neither party shall make any other use of the other party&#146;s name without the other party&#146;s
prior written approval.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If either of Bayer or Cumberland is impeded in fulfilling its undertakings in accordance
with this Agreement due to any cause beyond the reasonable control of Bayer or Cumberland, as
the case may be, such as, but not limited to fires, flood, earthquakes, lightening strike,
acts of God, catastrophic accident, terrorism, war, mobilization or unforeseen military
call-up of a large magnitude, requisition, confiscation, commandeering, public decrees, acts,
restraints, regulations or directions of governmental authorities, riots, insurrections,
general shortage of transport, goods, or energy and faults or delays in deliveries from
subcontractor or supplier caused by any circumstances referred to in this Paragraph&nbsp;11.10, the
impediment shall be considered a Force Majeure, and the party shall be exempted from liability
for delays due to such reasons, provided always that it notified the other party thereof
without undue delay after such a circumstance has occurred. Upon such notification, Bayer and
Cumberland shall agree upon a reasonable extension of the delivery time, not to exceed two (2)
months. If, after two (2)&nbsp;months following notification of the Force Majeure condition, such
condition persists, Cumberland may cancel the purchase orders affected by the Force Majeure
condition. Notwithstanding any of the foregoing, if any extension of the delivery time causes
hardship to Cumberland in the maintenance of its business, Cumberland may purchase its
Products requirements during such extension period from a third party as provided above.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither party shall have the right to control the activities of the other in the performance
of this Agreement, and each shall perform as an independent contractor, and nothing herein
shall be construed to be inconsistent with that relationship or status. Under no circumstances
shall the employees or agents of one party be considered employees or agents of the other.
This Agreement shall not constitute, create, or in any way be interpreted as a joint venture,
partnership, or formal business organization of any kind.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement, together with its attached Exhibits and the Quality Agreement and the
Services Agreement dated February&nbsp;6, 2008, constitutes the entire agreement between Bayer and
Cumberland with respect to the Manufacturing Services to be performed by Bayer. The
requirements of this Agreement supersede all prior understandings and agreements, whether oral
or written, all terms and conditions contained within any purchase order, acknowledgement,
invoice, or other agreement between Bayer and Cumberland with respect to the Manufacturing
Services. Other terms and conditions not inconsistent with the terms and conditions of this
Agreement covering Products to be supplied under this Agreement will be provided in purchase
orders and releases issued by Cumberland and in order acknowledgements and invoices issued by
Bayer. In the event of a conflict between the terms and conditions of any of these documents,
including the Quality Agreement, Bayer and Cumberland agree to negotiate in good faith to
resolve such differences, unless such terms conflict with the terms of this Agreement, in
which case the terms of this Agreement shall control.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer and Cumberland covenant and agree that subsequent to the execution and delivery of
this Agreement and without any additional consideration, each of Bayer and Cumberland shall
execute and deliver any further legal instruments and perform such acts which are or may
become necessary to effectuate the purposes of this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer and Cumberland agree to use their best efforts to resolve any and all disputes arising
out of or relating to this Agreement. If after thirty (30)&nbsp;days following receipt of notice by
one party from the other of a dispute under this Agreement, the parties are unable to resolve
the dispute, then the matter shall be fully and finally resolved in a court of law.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The heading of the Articles and Paragraphs used in this Agreement are included for
convenience only and are not to be used in construing or interpreting this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement may be executed in any number of counterparts, each of which will be deemed
an original, but all of which together will constitute one and the same instrument. Bayer and
Cumberland may rely upon facsimile signatures as binding execution of this Agreement and the
instruments contemplated hereby. Each of Bayer and Cumberland shall promptly send originally
executed versions of any documents or instruments bearing facsimile signatures to the other
party</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 13 of 23
</DIV>


<DIV align="left" style="margin-left: 9%; text-indent: -5%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">for record keeping purposes.</DIV>


<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in duplicate by their
respective duly authorized representatives, as of the date first written above.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BAYER HEALTHCARE, LLC</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Signature: <u>/s/ Dr.&nbsp;Detlef Mathes</u>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name: Dr.&nbsp;Detlef Mathes

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Title: Vice President of Operations

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Cumberland</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Signature: <U>/s/ A.J. Kazimi</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name: A.J. Kazimi

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Title: Chief Executive Officer

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 14 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Description of Manufacturing Services and One Time Costs

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quantities and Prices per Unit of Product

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Procedures for the Reporting of Adverse Drug Reactions

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Minimum Insurance Requirements

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 15 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT 1<BR>
DESCRIPTION OF MANUFACTURING SERVICES AND ONE TIME COSTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the event that improved technology relating to Manufacturing Services production or costs
(hereinafter &#147;Improvements&#148;) becomes known and available to Cumberland, then Cumberland may request
Bayer to investigate the feasibility of incorporating such Improvements into the Bayer&#146;s
production. Improvements are defined as quantifiable advantages in economic, functional, or quality
traits, and may include, but are not limited to, measurable improvements in Product integrity or
quality, efficiencies in production, consumer satisfaction, or reduced costs. Bayer and Cumberland
shall use their best efforts to implement cost, quality, and cycle time improvements. Cumberland
shall bear the costs of such investigation and incorporation of improvements in to Bayer&#146;s
production.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Project Scope Document</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cumberland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Annual Quantities: See Exhibit&nbsp;2</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bayer and Cumberland are to perform the following services related <B>to product development/product
transfer activities:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer to perform necessary scale up/engineering batch, demonstration batching to move
product to commercial manufacturing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer to source all materials required to perform scale up/product transfer and begin
to qualify all excipient materials.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland to provide and Bayer to transfer lab methods required to support scale up
and engineering batch production and cleaning validation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer to produce Cumberland recommended and mutually agreed upon amount and scale of
validation batches and prepare specified number of stability samples (if required).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer to develop validation documents and circulate for Cumberland approval and execute
protocols.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer to develop stability program protocols (if required), circulate for Cumberland
approval and execute protocols.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer to prepare final reports for validation and stability activities and provide to
Cumberland for inclusion in the regulatory submission, as appropriate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland will advise if any tight container testing is required. Bayer may develop
the protocols, for a fee, and perform that testing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cumberland will decide and perform any leechable or extractable testing required for
in-process or finish product containers.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bayer to perform the following services related to <B>commercial batch production:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on issuance of a purchase order by Company, manufacture commercial batch
quantities of Product.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Develop material specifications for all materials, identify suppliers of materials,
procure materials and manage material inventory levels (based on forecasts).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Using transferred laboratory methods for product engineering batch production/scale up
activities perform incoming material testing, in-process testing and final release
testing. Based on this testing a certificate of analysis will be issued, along with copy
of batch records, to Cumberland on a per batch basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Per batch, retained samples will be maintained and held by Bayer.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Develop ongoing sampling protocols for stability program and maintain samples (if
required)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Maintain waste material and Health and Environmental Saftey (&#147;HES&#148;) reporting for
ongoing production requirements.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 16 of 23
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Provide Cumberland audit access to manufacturing area and documents related to the
production of their product(s).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Ship lot quantities of finished and released vials to Cumberland, single point
location. Shipment will be FOB Shawnee, KS using the carrier/method of choice from
Cumberland.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bayer will not provide the following <B>support activities</B>:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Assistance in the recommendation for the components or facilitate the actual submission
of regulatory documents.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Assume the commercial viability of this formulation and/or packaging configuration of
this product in the marketplace, except as otherwise set forth in the Manufacturing
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Performance/assurance of the product regarding scalability. Cumberland is requested to
be present, support and approve all follow up Bayer scale up activities and share in
accepted performance (and costs) of the product during those scale up activities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Assure the accuracy/reliability of original laboratory methods.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Support or make claims about the placement of this product in the marketplace.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">One Time Costs:</DIV>


<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">See Attachment I for Ibuprofen Inj One-Time Costs<BR>
See Attachment II for Acetadote Inj One-Time Costs</DIV>


<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Both One-Time Costs have been readjusted to account for the reduced Acetylcysteine unit price.
Both contain the manufacturing/ filling cost for one engineering feasibility study. A second
engineering/ feasibility study for either product would cost:</DIV>


<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Ibuprofen Inj: &#091;***&#093;<BR>
Acetadote Inj: &#091;***&#093;</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 17 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>ATTACHMENT I</I></B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="50%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Cumberland Pharmaceuticals, Inc.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>One Time Costs &#151; Ibuprofen Inj</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/7/2007</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 18 of 23
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">&#091;***&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 19 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>ATTACHMENT II</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="50%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Cumberland Pharmaceuticals, Inc.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><I>One Time Costs &#151; Acetadote Inj.</I></B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/7/2007</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;***&#093;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 20 of 23
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 21 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT 2<BR>
QUANTITIES AND PRICES PER UNIT OF PRODUCT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">&#091;***&#093;
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Page 22 of 23
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT 3</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROCEDURES FOR REPORTING OF ADVERSE DRUG REACTIONS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(See Quality Agreement)
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT 4</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MINIMUM INSURANCE REQUIREMENTS
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.0</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commercial General Liability Insurance:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Bayer and Cumberland shall each maintain a policy or policies of commercial general liability
insurance with the premiums thereon paid on or before the due dates, issued by and binding upon a
solvent insurance company authorized to transact business in the state where the insured party
resides. Such insurance shall be written on an occurrence basis and shall afford minimum
protection (which may be affected by primary and/or excess coverage) of not less than $2&nbsp;million
per occurrence for bodily injury and property damage.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.0</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Workers&#146; Compensation</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Bayer and Cumberland shall maintain Statutory Coverage for Workers&#146; Compensation.</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.0</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Product Liability</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-left: 2%; text-indent: 0%; margin-right: 0%; font-size: 10pt; margin-top: 6pt">Bayer and Cumberland shall maintain Product Liability Insurance &#091;***&#093; Each Occurrence and in the
Aggregate</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Basis of Insurance</U>:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All policies, other than for Product Liability, shall be issued on an &#147;occurrence&#148; basis
unless such coverage is not available on commercially reasonable terms. Where insurance is on
a &#147;Claims Made&#148; basis, each Party shall maintain the coverage until the later of the
expiration of three years after the manufacture of the final batch of Product by Bayer or of
all applicable statutes of limitations. Each Party shall list the other Party as an
additional insured.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Product Liability policy shall be issued on a &#148;Claims Made&#148; basis. Each Party shall
maintain the Product Liability coverage until the later of the expiration of three years after
the manufacture of the final batch of Product by Bayer or the applicable statute of
limitations.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bayer reserves the right to self-insure for any and all coverages.</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>g06286b1exv23w1.htm
<DESCRIPTION>EX-23.1 CONSENT OF KPMG LLP
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-23.1 CONSENT OF KPMG LLP</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXHIBIT&#160;23.1</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consent
    of Independent Registered Public Accounting Firm</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cumberland Pharmaceuticals&#160;Inc.:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We consent to the use of our report included herein and to the
    reference to our firm under the heading &#147;Experts&#148; in
    the prospectus.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>


<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="g06286b1g0628610.gif" alt="KPMG" >
</DIV>



<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Nashville, Tennessee
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    May&nbsp;21, 2008
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g06286b1g0628610.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g06286b1g0628610.gif
M1TE&.#EAC``=`(```````/___R'Y!```````+`````",`!T```+_C(^I!NL/
MHYRTVJM`P[S[#TJ:%I;FB28CF;;N&ZWP3'-;/-;Z'N/K+^,)7RP'\(@,Y8:[
M8@8)!7J"S)KS0'U<`UG$;;&L?E5C6[D+WG*7MS!9K8.O&5&W]XLVPG-L=9Y^
M="(W"$6&)9>FM\%GM];HF&1"J.641?)'F<9R^9@G151V2'F&]W-A9PK8%7B'
M*!G*`.'7]EE11\OXYM@*F[+7._=TF&I;R$LWO%B$Z0N+>.6VR?SV1\6YC.TJ
MZ-S+N#KVJ"E2^8W+'77Z.PH<?.PS#KX5YEF',:DW,>L:?E=<JMW.7K>!^<X!
M`P@0$#5V`2UTNM:GH"Q^%!+N6GA/X*U/*`C9$;-B\%8'8Q^1O2KI@I!()A8=
64GSELF65F?YHVKPI\Z;.G3P7%```.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
